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RÉSUMÉ 
Les maladies cardiovasculaires (MCV) demeurent au tournant de ce siècle la principale 
cause de mortalité dans le monde. Parmi les facteurs de risque, l’hypercholestérolémie et 
l’obésité abdominale sont directement liées au développement précoce de l’athérosclérose. 
L’hypercholestérolémie familiale, communément associée à une déficience des récepteurs des 
lipoprotéines de basse densité (LDLR), est connue comme cause de maladie précoce 
d’athérosclérose et de calcification aortique chez l’humain. La subtilisine convertase 
proprotéine/kexine du type 9 (PCSK9), membre de la famille des proprotéines convertases, est 
trouvée indirectement associée aux MCV par son implication dans la dégradation du LDLR. Chez 
l'humain, des mutations du gène PCSK9 conduisent soit à une hypercholestérolémie familiale, 
soit à une hypocholestérolémie, selon que la mutation entraîne un gain ou une perte de fonction, 
respectivement. Il demeure incertain si les individus porteurs de mutations causant un gain de 
fonction de la PCSK9 développeront une calcification aortique ou si des mutations entraînant une 
perte de fonction provoqueront une obésité abdominale. Dans cette étude, nous avons examiné : 
1) l’effet d’une surexpression de PCSK9 dans le foie de souris sur la calcification aortique ; 2) les 
conséquences d’une déficience en PCSK9 (Pcsk9 KO), mimant une inhibition pharmacologique,  
sur le tissu graisseux. 
Nous avons utilisé un modèle de souris transgénique (Tg) surexprimant le cDNA de PCSK9 
de souris dans les hépatocytes de souris et démontrons par tomographie calculée qu’une 
calcification survient de façon moins étendue chez les souris PCSK9 Tg que chez les souris 
déficientes en LDLR. Alors que le PCSK9 Tg et la déficience en LDLR causaient tous deux une 
hypercholestérolémie familiale, les niveaux seuls de cholestérol circulant ne parvenaient pas à 
prédire le degré de calcification aortique. Dans une seconde étude, nous utilisions des souris 
génétiquement manipulées dépourvues de PSCK9 et démontrons que l’accumulation de graisses 
viscérales (adipogenèse) apparaît régulée par la PCSK9 circulante. Ainsi, en l’absence de 
PCSK9, l’adipogenèse viscérale augmente vraisemblablement par régulation post-traductionnelle 
des récepteurs à lipoprotéines de très basse densité (VLDLR) dans le tissu adipeux.  
Ces deux modèles mettent en évidence un équilibre dynamique de la PCSK9 dans des voies 
métaboliques différentes, réalisant un élément clé dans la santé cardiovasculaire. Par 
conséquent, les essais d’investigations et d’altérations biologiques de la PCSK9 devraient être 
pris en compte dans un modèle animal valide utilisant une méthode sensible et en portant une 
attention prudente aux effets secondaires de toute intervention. 
Mots clés: 
Subtilisine convertase proprotéine/kexin type 9, récepteur des lipoprotéines de faible 
densité, hypercholestérolémie familiale, calcification aortique, métabolisme des graisses. 
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ABSTRACT  
Cardiovascular disease (CVD) is the leading cause of death in the 21st century. 
Among risk factors, hypercholesterolemia and abdominal obesity are directly linked to 
premature development of atherosclerosis. Familial hypercholesterolemia, commonly 
due to low-density lipoprotein receptor (LDLR) deficiency, is known to cause premature 
atherosclerosis and aortic calcification in humans. Proprotein convertase subtilisin/kexin 
9 (PCSK9), a member of the proprotein convertase family, is indirectly associated with 
CVD through enhanced LDLR degradation. Mutations in the human PCSK9 gene lead to 
either familial hypercholesterolemia or hypocholesterolemia, depending on whether the 
mutation causes a gain or a loss of function, respectively. It is uncertain if individuals 
carrying mutations causing a gain-of-function of PCSK9 will develop aortic calcification 
or whether loss-of-function mutations will lead to abdominal obesity. In this thesis, we 
investigated: 1) the effect of PCSK9 overexpression on aortic calcification; 2) the 
consequences of PSCK9 deficiency, mimicking pharmacological inhibition of PCSK9 on 
fat tissue. 
We employed a transgenic (Tg) mouse model overexpressing mouse PCSK9 and 
illustrated by micro-computerized tomography that calcification occurs to a lesser extent 
in PCSK9 Tg mice than in LDLR-deficient mice. While both PCSK9 Tg and LDLR 
deficiency caused familial hypercholesterolemia, circulating cholesterol levels alone 
could not dictate the degree of aortic calcification. In another study, we used genetically 
modified mice lacking PCSK9 and demonstrated that visceral fat accumulation 
(adipogenesis) is regulated by circulating PCSK9. Thus in the absence of PCSK9, 
visceral adipogenesis increases likely via post-translational regulation of very-low-
density lipoproteins receptors (VLDLR) in the adipose tissue.  
In conclusion, these two studies highlight the dynamic balance of PCSK9 in different 
metabolic pathways, making it a key element in cardiovascular health. Consequently, 
attempts to survey and/or alter PCSK9 biology should be performed in a valid animal 
model using sensitive methods and with careful attention to side effects of any given 
intervention. 
 
Key words:  
Proprotein convertase subtilisin/kexin 9, low-density lipoprotein receptor, familial 
hypercholesterolemia, aortic calcification, fat metabolism.
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CHAPTER 1 
LITERATURE REVIEW  
 
1. Pandemic of cardiovascular disease 
Cardiovascular disease (CVD) is the number one killer disease in developed 
countries (Murray et al 1997, Yusuf et al 2001). According to the World Health 
Organization (WHO) report this has been also the case in developing countries during 
last year (WHO 2011). The rapid urbanization of the developing world has led to the 
pandemic of CVD with significant impact on individuals, societies and global well-being 
(Ruff et al 2010). It is estimated that around 80% of CVD deaths will strike low- to 
middle-income countries with limited medical resources. In less than 20 years close to 
24 millions of individuals will die from CVD worldwide. The largest percentage will occur 
in the Middle East and the largest absolute number of deaths alone will take place in the 
Indian subcontinent and the Far East (WHO 2011). 
This is in accord with epidemiological studies provided insight into the shifting 
etiology of CVD from the drastic infection-related rheumatic heart and syphilitic aortitis 
(Nakazone et al 2010) to an insidious and slowly progressing etiology related to physical 
inactivity and caloric excess. This shift has led to the blowup of secondary dyslipidemia 
that gradually emerged from affluent societies to less wealthier ones. The emphasis 
today is to tackle modifiable risk factors such as hypercholesterolemia and improve 
treatment strategies to lessen this burden (Ruff et al 2010). 
In this chapter I will discuss hypercholesterolemia and abdominal obesity and the 
challenges facing disease detection and cure. Chapter 2 will be an application of an 
imaging method extensively used in human studies that has been applied to two 
hypercholesterolemic animal models to evaluate arterial calcification. Chapter 3 will 
explore the effect of a hypothetical pharmacological approach to treat 
hypercholesterolemia and the potential abdominal obesity as a side effect.  Finally I will 
conclude and summarize the overall progress in Chapter 4. 
 
1.1. Risk factors 
Diabetes mellitus, abdominal obesity and hypercholesterolemia are among the top 
modifiable risk factors of CVD along with hypertension and smoking (Yusuf et al 2004). 
Individuals with features of the first three risk factors are diagnosed with the metabolic 
syndrome and therefore at a higher risk of atherosclerosis and vascular calcification 
                                                                                                                                                                  3  
(Ellison et al 2005) (Table I). Other important behavioral risk factors of CVD are Western 
diet and inactivity. 
  
Table I: Risk factors for cardiovascular disease † 
Risk factor Population-attributable risk (%) 
Diabetes mellitus * 
No exercise  
No fruit and vegetable intake  
No alcohol intake  
Hypertension  
Psychosocial factors ‡ 
Abdominal obesity * 
Current smoking  
Hypercholesterolemia*  
(High Apo B:Apo A1 ratio)  
12.3 
12.5 
12.9 
13.9 
23.4 
28.8 
33.7 
36.4 
54.4 
†From the INTER-HEART study. * Risk factors for atherosclerosis and arterial 
calcification.  ‡Depression, perceived stress at home or work (general stress), low locus 
of control, and major life events. (Abbreviations: Apo, apolipoprotein; MI, myocardial 
infarction). Taken from Ruff et al. Nat. Rev. Cardiol; 2010. 
 
Behavioral risk factors are responsible for about 80% of CVD and are usually 
modifiable, but genetic risk factors including gender and age, are not (Ruff et al 2010). 
Adherence to treatment guidelines to modify risk factors is a current priority. Although 
not always easy to treat, failing to succeed in reducing modifiable risk factors will 
aggravate chronic illness to a new unanticipated dimension. Along the same lines, 
advancement in biomedical research leading to our better understanding of complex 
disease should translate into higher and earlier detection rate that will most certainly 
enhanced treatment modalities and engender new pharmacological approaches. 
 
1.1.1. Hypercholesterolemia 
Hypercholesterolemia is caused by excessive circulating cholesterol levels above the 
95th percentile of a given population (Bae et al 1993). Hypercholesterolemia is a well 
known risk factor to CVD (Goldstein et al 1987). In the INTER-HEART study (an 
international heart study designed to assess the importance of risk factors on CVD 
worldwide) it had the highest attributable risk (54%) for development of myocardial 
infarction (Ruff et al 2010) (Table I). In order to understand how excess cholesterol may 
leads to medical complications we have to study how cholesterol is carried in the blood 
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and the essential role of different players and mediators like the essential role of the low-
density lipoprotein receptor (LDLR) in disease progression and treatment. 
 
1.1.1.1. Lipid metabolism and the role of LDLR 
Lipoprotein particles including chylomicrons, very-low density lipoprotein (VLDL), 
intermediate density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density 
lipoprotein (HDL) carry cholesterol in the blood. Lipoprotein particles also transfer and 
accept cholesterol, triglycerides (TG) and proteins from other lipoprotein particles and 
tissues. These lipoprotein particles are separated and classified according to their 
densities and diameters that reflect their load of cholesterol, TG and 
apolipoproteins (Figure 1) (Grundy et al 1990). A single lipoprotein particle is usually 
composed of apolipoproteins, phospholipids, TG, free cholesterol and cholesteryl esters.  
 
 
 
Figure 1. Lipoprotein classes and subclasses. A lipoprotein particle is composed 
of apolipoprotein, phospholipids, triglycerides, cholesterol and cholesteryl esters. 
Taken from Grundy et al. Cholesterol and atherosclerosis; 1990.  
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Lipoproteins are subjected to plasma and tissue enzyme actions and are removed 
from the circulation through receptor–mediated uptake by three pathways (Brown et al 
1983, Von Eckardstein et al 2001) (Figure 2): 
1. The exogenous pathway, which dictates the fate of dietary lipids.  
2. The endogenous pathway, which dictates the fate of lipid synthesized in liver.  
3. The reverse cholesterol transport pathway, which dictates the fate of peripheral 
tissue lipids and the excess return back to the liver.  
 
 
 
Figure 2. Lipid metabolism; exogenous, endogenous and reverse cholesterol transport 
pathways are depicted. VLDL, CM and HDL initial and mediate the exogenous, 
endogenous and reverse cholesterol transport processes respectively in the human body. 
(Abbreviation – ABCA1: ATP-binding cassette 1, CETP: Cholesteryl ester transfer protein, 
CM: chylomicron, FFA: free fatty acid, HDL: high-density lipoprotein, IDL: intermediate-
density lipoprotein, LCAT: lecithin:cholesterol acyl transferase, LDL: low density 
lipoprotein, LPL: lipoprotein lipase, PLTP: phospholipid transfer protein, VLDL: very low 
density lipoprotein). Taken from Marcil M et al. Hypoalphalipoprotéinémie familiale. 
Aspects cliniques, génétiques, cellulaires et moléculaires. Doctoral Thesis, Université de 
Montréal, 1999; p. 17. 
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The exogenous pathway. The intestinal epithelium assembles dietary TG and 
cholesterol, along with apolipoproteins (apo) B-48 and apoA and phospholipids into 
chylomicron (CM) particles. This facilitates its travel inside the aqueous plasma to deliver 
lipid to different tissue after having a meal. Following their secretion into the plasma, an 
exchange of components takes place between chylomicrons and HDL, wherein plasma 
the cholesterol, apoE, apoC-II, apoC-III and phospholipids are transferred from HDL to 
chylomicrons and apoA is transferred from chylomicrons to HDL. ApoC-II in the 
chylomicrons activates the lipoprotein lipases (LPL) found on the epithelium of the 
muscle and adipose tissue (Saxena et al 1991) and associated with heparan sulfate 
proteoglycans (HSPG). When a VLDL particle docks on a VLDL receptor (VLDLR), the 
TG in the core are hydrolyzed by LPL. Newly liberated free fatty acids (FFA) then enter 
either the muscle cells (metabolized for energy via β-oxidation) or the adipocytes 
synthesized back to TG for storage (Jensen et al 2003). As a result, the chylomicrons 
shrink in size and apoC-II, apoC-III, phospholipids and free cholesterol are transferred 
back to HDL particles. Chylomicron remnants containing apoB-48, apoE and cholesteryl 
esters are internalized and catabolized after binding the hepatic apoE receptor (Brown et 
al 1983, Gregory et al 2001). 
 
The endogenous pathway. De novo synthesized lipids by the liver are incorporated in 
nascent VLDL particles. These VLDL, contain TG, cholesterol, apoB-100 and 
phospholipids assembled and secreted by the hepatocytes into the plasma when the 
body is in a fasting state. In the plasma, apoC-II, apoC-III and apoE are transferred to 
VLDL from HDL. Apo C-II activates LPL to hydrolyze TG from VLDL and yield a smaller 
and denser intermediate-density lipoprotein (IDL) particle. Some IDLs particles are 
removed by the liver via an apoE receptor (Brown et al 1983), while the remaining 
particles transfer CE to HDL in exchange for TG. Conversion of IDL to LDL is complete 
after the cholesteryl esters are transferred from HDL to IDL, while TG and 
apolipoproteins (except apo B-100) are removed from IDL. LDL delivers cholesterol to 
hepatocytes and peripheral cells (e.g. adrenal gland) via LDL receptor (LDLR) uptake. 
Scavenger cells (e.g. macrophages) in blood vessels may pick up oxidized LDL 
particles, in case of hypercholesterolemia, leading to atherosclerotic plaque formation 
(Brown et al 1983, Gregory et al 2001). 
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Reverse cholesterol transport. HDL particles mediate the return of cholesterol from 
peripheral cells to the liver to protect the vessels form the harmful effect of excess lipids. 
Nascent HDL particles containing apoA1, apoE are assembled and secreted by the liver 
and intestine. Free cholesterol from other lipoproteins or peripheral cells is transferred to 
HDL and esterified by LCAT. The cholesteryl esters can be transferred to other 
lipoproteins such as IDL and LDL to be derived back to the liver or transported directly 
by HDL particles to the liver through scavenger receptor class B type I (SR-BI) (Von 
Eckardstein et al 2001). 
 
The LDLR is mainly a hepatic cell surface receptor (Brown et al 1983) that 
recognizes the apoB-100 ligand, but also apoE carried on VLDL remnant, IDL and some 
classes of HDL (Innerarity et al 1990, Kane et al 2001). Shortly after the LDLR discovery 
in 1979, Brown and Goldstein won the Nobel Prize for what was considered the key 
element in the cholesterol endogenous pathway (Brown et al 1983).The receptor-
mediated endocytosis of the LDL particles by LDLR occurs in most, but not all, cells in a 
clathrin coated vesicles assisted by the adapter proteins ARH (Garcia et al 2001). Then 
when internalized the low pH in the vesicles facilitate the dissociation of the LDLR from 
its ligand. LDLR then recycles back to the surface to be associated with more LDL 
particle and eventually cholesterol levels fall in the circulation (Goldstein et al 1985). The 
liver then utilizes the cholesterol and TG to synthesize VLDL particles which are then 
exported once again to the circulation and/or excreted in the intestine as bile acids.  
 
The LDLR is a 839-amino acids transmembrane glycoprotein that is encoded on 
chromosome 19 (Brown et al 1987) (Figure 3). Its N-terminal ligand-binding domain is 
292-amino acids long that compose a cysteine-rich sequence. Its C-terminal cytoplasmic 
domain composes 50-amino acids long and serves to direct the receptor to the coated 
pits. In addition the extracellular portion of the receptor contains a 22-amino acid 
membrane-spanning region, a 58-amino acid region of 18 O-linked carbohydrate chains 
and a 400-amino acid region that is homologous to the precursor for epidermal growth 
factor (EGF) (Brown et al 1987).  
                                                                                                                                                                  8  
 
Figure 3. The LDL receptor superfamily. The structural organization of some 
members of the LDL receptor gene family is depicted. The closest member to the 
LDLR is the VLDLR followed by the ApoER2.  Taken from Schneider et al. J Am 
Soc Nephrol; 1999.  
 
The EGF precursor homology domains consist of EGF repeats and YWTD spacer 
regions whish are involved in the pH-dependent release of the ligands from LDLR. The 
LDLR belongs to the LDLR superfamily that shares structural similarity with members of 
the LDL receptor gene family (Figure 3). Sequence alignment programs revealed that 
the closest members to the LDLR in structure were VLDLR (59% identity) and 
apolipoprotein E receptor 2 (ApoER2) (46% identity) followed by LRP, Megalin and C-
elegans receptor (Poirier et al 2009). 
 
There are over one thousand mutations identified in the LDLR gene to date 
(Guardamagna et al 2009) and they are classified into the 4 following groups (Goldstein 
et al 1987, Hobbs et al 1990): 
1. Null mutations or LDLR defective synthesis (e.g. >15kb deletion in LDLR genes, a 
common French-Canadian mutation). 
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2. LDLR defective transport from the endoplasmic reticulum (ER) to the trans-Golgi 
network (TGN) (or gain-of-function mutation in PCSK9 gene which targets intra-
cellular LDLR). 
3. LDLR defective binding (or loss of function mutation in APOB gene encoding the 
apoB-100 ligand). 
4. LDLR defective internalization where receptors do not cluster in the coated pits, 
thereby minimizing LDL internalization (e.g. mutations in autosomal recessive 
hypercholesterolemia “ARH” gene encoding the adaptor protein ARH). 
 
1.1.1.2. The etiology of hypercholesterolemia 
Monogenic hypercholesterolemia (or familial hypercholesterolemia - Fredrickson 
classification IIa) is the most common cause of markedly elevated serum cholesterol 
concentrations. Familial hypercholesterolemia (FH) is diagnosed by plasma low-density 
lipoprotein cholesterol (LDL-C) elevations 2-fold (heterozygote) or 3- to 5-fold 
(homozygote) above the average of a given population, age- and gender–matched, 
while serum TG concentrations remains within normal range (Rader et al 2003). Mixed 
hypercholesterolemia (familial combined dyslipidemia, Fredrickson classification IIb) has 
both LDL-C and TG elevations. This condition is caused by a susceptible genotype 
aggravated by one or more risk factors, including atherogenic diet (saturated fat, trans-
fat, and cholesterol) (Hu et al 1997), obesity, and lack of exercise. Monogenic 
hypercholesterolemia is associated with xanthelasma and cutaneous xanthomas that 
can be sometimes extensive and disfiguring in homozygous FH. More importantly, 
affected FH patients are at increased risk for premature coronary artery disease and 
death at a younger age. Homozygous FH can experience their first cardiac event in 
childhood and only few survive to reach adulthood (Awan et al 2008).   
 
The carrier frequency of mutations leading to FH in the general population is 1:500 
(Brown et al 1983); however, this frequency increases in the French-Canadian descent 
who may suffer the “founder effect” of the first French settlers. This is due to many years 
of geographical isolation and a small genetic pool. The carrier frequency in some of the 
rural sites in Quebec can reach 1:80 (Scriver 2001). This phenomenon can be observed 
not only in the French-Canadian population but in similar culturally isolated environments 
in South-Africa and in some regions of Italy, Scandinavia and Lebanon (Khachadurian 
1964). 
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From a practical point of view, human mutations in FH are of two major types 
depending on LDLR residual activity: < 2% (receptor-negative, poor response to statin) 
or between 2-25% (receptor-defective, good response to statin) (Rader et al 2003). Thus 
levels of residual LDLR activity correlates negatively with plasma levels of LDL-C. 
Etiologically speaking hypercholesterolemia can be a problem of cholesterol clearance 
(primary) or a problem of over production (secondary): 
A. Primary or genetic etiologies are collectively called FH; classically a monogenic 
disorder caused by mutations in LDLR gene leading to either an absence or low 
activity of the LDLR. Since LDLR seminal discovery by Brown et al, three additional 
gene mutations have been discovered as primary cause of FH (Figure 4):  APOB 
gene (FDB, familial defective apolipoprotein B) (Humphries et al 2006), ARH gene 
(encoding the adaptor protein, also known as autosomal recessive 
hypercholesterolemia) (Garcia et al 2001) and the recently described gain-of-function 
mutations in PCSK9 gene. PCSK9 will be discussed in greater details in Section 2. 
 
 
Figure 4. LDLR recycling and associated genetic defect. Familial 
Hypercholesterolemia (FH) is caused by mutations in LDLR gene leading 
to either an absence or low activity of the LDLR, mutations in APOB gene 
(Familial defective apolipoprotein B), mutations ARH gene (Autosomal 
Recessive Hypercholesterolemia) or gain-of-function mutations in PCSK9 
gene (encoding the LDLR regulatory protein). 
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B. Secondary or acquired etiologies of hypercholesterolemia may include metabolic 
disorders like liver disease (bile duct obstruction), renal failure (nephrotic syndrome) 
(Awan et al 2009) and hypothyroidism (Abrams et al 1981). 
 
1.1.1.3. Treatment of hypercholesterolemia  
Before the statin era, cholestyramine (bile acid binder) and niacin (vitamin B3 analog) 
(Goldstein et al 1987, Grundy et al 1981) were among the commonly used drugs to 
lower cholesterol, but were limited in usage due to their intolerability. Statins on the other 
hand represent a class of medication that inhibits the hydroxymethyl glutaryl coenzyme 
A (HMG-CoA) reductase (Goldstein et al 1987), a rate limiting enzyme in endogenous 
cholesterol synthesis. As a consequence statins, by reducing the endogenous levels of 
cholesterol synthesis, increase the uptake of circulating LDL particles, with significantly 
lower side effects leading to higher patient compliance. The mechanism of statins’ action 
is mediated by the upregulation of the levels of cell surface LDLR, which is found 
ubiquitously in all cells, but predominantly in hepatocytes (Goldstein et al 1987). 
Upregulation of the LDLR at the surface of hepatocyte increases LDL particles uptake in 
the liver and effectively lowers plasma cholesterol in blood (Goldstein et al 1987). The 
LDLR gene is under the influence of sterol regulatory element binding protein 2 (SREBP-
2) which binds specific sterol regulatory elements in the promoter of the LDLR gene, 
thus up regulating the expression of LDLR in response to low sterol (Horton et al 2002). 
The transcription factor SREBP-2, in response to statin, also upregulates a molecule 
termed PCSK9 to counter regulate the LDLR effect (Dubuc et al 2004). PCSK9 binds to 
the LDLR via its catalytic domain, which interacts with the epidermal growth factor (EGF) 
A domain on the extracellular region of the LDLR (Zhang et al 2007) (Figure 3). The 
EGF precursor domain modulates LDL particle binding to the LDLR and mediates the 
acid-dependent dissociation of the ligand from the LDLR. Although the EGF-like repeats 
on LDLR are homologous to other LDLR family members (Christensen et al 1999) 
(Figure 3), there was no in vivo evidence (until our study) that PCSK9 binds other 
members of the LDL receptor gene family like the closely related VLDLR and the 
apoER2, although this was reported in cell lines (Poirier et al 2008).  
 
Statins not only increase LDLR and decrease cholesterol levels, but also have been 
associated with a 20-25% reduction in CVD in over 14 randomized clinical trials (Baigent 
et al 2005). The additional protective role on CVD beyond cholesterol lowering can be 
                                                                                                                                                                  12  
explained by the pleiotropic effects of statins (Davignon et al 2004). These pleiotropic 
properties influence various aspects of cell functions, inflammation, coagulation and 
vasomotor activity (De Lorenzo et al 2006). However, in patients lacking LDLR or having 
significantly lower LDLR activity, the statin class of medications is not efficient to lower 
cholesterol on their own, and ezetimibe (Rader et al 2003), a class of specific inhibitors 
of intestinal cholesterol absorption, are usually added. If all pharmacological attempts to 
lower cholesterol fail, a drastic invasive technique, LDL apheresis (Rader et al 2003), is 
then required. LDL apheresis, a type of dialysis to filtrate lipoproteins, has allowed 
homozygous FH patients to live beyond their life expectancy; however they are not free 
of disease as they experience arterial calcification as a late complication of the original 
disease (Awan et al 2008).  
 
In summary lipoproteins and lipoprotein disorders play an important role in the onset 
and progression of CVD. Available treatments to date, including statins and LDL 
apheresis, are not sufficient to eliminate cardiovascular risk and the search for newer 
and safer cholesterol-lowering agents continues. Therefore, classes of drugs, such as 
the PCSK9 inhibitors are viable candidates, as will be discussed in section 2. 
 
 
1.1.2. Abdominal obesity  
A state of excess visceral fat in the abdomen is termed abdominal obesity. The WHO 
terms abdomen obesity a worldwide epidemic. Public health leaders marked obesity and 
inactivity as the second leading cause of preventable deaths in the West (Mokdad et al 
2005). In the INTER-HEART study (an international heart study designed to assess the 
importance of risk factors on CVD worldwide) abdominal obesity carried a 33.7% 
attributable-risk of developing myocardial infarction (Table I). The WHO was also 
alarmed by the rise of childhood obesity (Koletzko et al 2002). Excess calories in 
children fuel the formation of new adipocytes and lead to hyperplastic obesity. This 
differs from adulthood caloric-excess that leads to hypertrophic obesity. Individuals with 
hyperplastic obesity are more likely to encounter difficulties in losing weight, since diet 
alone decreases the size but not the number of adipocytes. Childhood overweight and 
obesity is associated with higher CVD risk (Teixeira et al 2001) and the persistence of 
obesity is linked to the development of multiple risk factors (Srinivasan et al 1996), which 
in addition to developing CVD may lead to diabetes and cancer (Haslam et al 2005). 
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One billion adults and one tenth of the world’s children are now classified as overweight 
or obese and will experience diminished life expectancy (Haslam et al 2005). For 
instance obesity has been shown to decrease life expectancy by 7 years at the age of 40 
(Peeters et al 2003).  
 
1.1.2.1. Fat metabolism and the role of VLDLR 
Similar to the LDLR in hepatocytes, the very-low-density lipoprotein receptor 
(VLDLR) plays a major role in adipocyte fat metabolism. VLDLR is highly expressed in 
adipose tissue (Takahashi et al 2004, Tacken et al 2001). In rabbits, the mRNA 
expression of VLDLR was significant in muscles and adipose tissues, but not detectable 
in the liver. This indicates a key role of VLDLR in the fatty acid metabolism of peripheral 
tissues (Oka et al 1994). Different from the LDLR, the VLDLR is not regulated by cellular 
sterols and does not bind efficiently LDL particles. However estradiol, thyroid hormone 
and active vitamin D modulate VLDLR expression (Tacken et al 2001). Feeding status 
per se did not influence mRNA levels of VLDLR, but atherogenic diets upregulate the 
expression of VLDLR in different animal models (Tiebel et al 1999). 
 
Initially the involvement of VLDLR in lipoprotein metabolism could not be easily 
illustrated using a VLDLR knockout mouse. Apart from a 15-20% adipose mass 
reduction, lipid parameters were not significantly altered (Frkman et al 1995). It was only 
later, when VLDLR and LDLR double knockout mice became available, that the 
contribution to fatty acid delivery from TG-rich lipoprotein particles in peripheral tissues 
was elucidated (Tacken et al 2000). VLDLR-deficient mice were protected against diet-
induced obesity and insulin resistance (Goudriaan et al 2000). VLDLR binds apoE-
enriched chylomicrons and VLDLs, IDLs, as well as LPL that hydrolyzes TG into FFA 
(Figure 5). These interactions are facilitated by HSPG that binds LPL as well (Takahashi 
et al 2004, Tacken et al 2001), whereas binding to ApoC-I, inhibits FFA hydrolysis (Jong 
et al 1996). Once the binding is facilitated by VLDLR (Figure 5), LPL starts to hydrolyze 
TG from TG-rich particles and FFAs diffuse into the cell were they become esterified or 
reform back to TG and contribute to the lipid core. 
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Figure 5. The VLDLR role in fat metabolism. The VLDLR and HSPG facilitate 
LPL proximity to VLDL leading to TG hydrolysis and FFA entry to the cell. Taken 
and modified from Tacken et al. Curr Opin Lipidol; 2001. 
 
 
1.1.2.2. The etiology of obesity  
A simplified mechanism of obesity is energy disequilibrium leading to excessive 
calories stored in adipose tissue when energy expenditure is reduced (Rosenbaum et al 
1997). However, the exact mechanism of obesity is not fully understood and is likely 
multifaceted (Bouchard et al 1991) (Figure 6). Evidence to support the fact that obesity 
is under genetic influences comes from identical twins studies (Bouchard et al 1990). 
Depending on the method used, genetic variation is estimated to account for up to 50% 
of the weight variability (Bluchard et al 1988). The total transmission effect to obesity 
represents 35% when estimated by body mass index (BMI), but only 5% are linked to a 
genetic defect (Bouchard et al 1991). Hence, in contrast to overall weight, BMI is more 
sensitive to lifestyle and environmental conditions. Genetics can explain up to 25% of 
the individual differences in percent body fat and mass (Bouchard et al 1991). Therefore 
genetic predisposition alone does not necessarily translate into obesity. Although the 
transmission of a way of life and some genetic factors influence how the body regulates 
appetite and energy expenditure (Grundy et al 1998), the total transmission effect alone 
could not contribute significantly to the endemic rise of obesity (Figure 6). Therefore 
classification of obesity by genetic means may require more studies (Pi-Sunyer 2000).  
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Figure 6. Etiology of obesity: genetic vs. non-genetic factors. 
Total transmissible variance and its genetic component for body 
mass index (BMI), subcutaneous fat (skin-fold thickness) and for 
total body fat from underwater weighing. Taken from Bouchard et 
al. Am J Clin Nutr; 1991. 
 
 
The only fully studied gene that causes direct obesity is the gene leading to 
congenital leptin deficiency (Rosenbaum et al 1997). Mouse model simulating the 
human disease is designated ob/ob mice and becomes morbidly obese and insulin 
resistant on a regular diet (Ingalla et al 1950). Conversely polygenic mutation in over 15 
genes has been linked to Bardet-Biedl syndrome that is characterized by obesity, mental 
retardation, and hypogonadism (Green et al 1989, Farooqi et al 2005). Interestingly, 
single-nucleotide polymorphism (SNP) in the gene termed proprotein convertase 1 gene 
(PCSK1) leads to hypoinsulinemia and elevated proinsulin and pro-opiomelanocortin 
(POMC). These SNPs were associated with severe childhood obesity (Heni et al 2010, 
Farooqi et al 2004). 
 
On the other hand, environmental factors such as eating habits and physical 
inactivity play a major role in weight gain in westernized communities. The type and 
quantity of refined carbohydrates and saturated fat consumed is a direct cause of the 
alarming incidence of obesity (Hu FB 2010). Obesity usually gives rise to many chronic 
diseases such as hypertension, diabetes, dyslipidemia and CVD (Haslam et al 2005). 
Obesity can also be a side effect of chronic diseases such as in Cushing's syndrome 
and hypothyroidism, but the cause of obesity is sometimes hard to distinguish (Longe et 
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al 2006). For instance, depression in patients may be a cause of obesity, or commonly 
depression may lead to overweight and obesity (Table II). Antipsychotic and 
antidepressant medications per se may increase weight likely by activating the SREBP 
transcription factors as seen in human primary hepatocytes, with subsequent up-
regulation of downstream genes involved in cholesterol and fatty acid biosynthesis 
(Raeder et al 2006). A list of medications that may lead to weight gain and obesity are 
indicated in Table II. Therefore, whenever designing newer drugs that influence lipid 
metabolism, weight gain must be examined. 
 
Table II: Medications that may lead to weight gain and obesity 
• Antipsychotics: especially olanzepine 
• Antidepressants: tricyclics, selective serotonin-reuptake inhibitors, monoamine 
oxidase inhibitors, mirtazepine, lithium 
• Anticonvulsants: phenytoin, sodium valproate 
• Antihistamines: many antihistamines, though weight gain is greater with older 
agents. 
• Antimigraine: pizotifen, used as a prophylactic migraine treatment 
• Corticosteroids 
• Oral contraceptive and progestagenic compounds 
• β-blockers 
• Oral hypoglycaemic agents: glitazones (peripheral rather than visceral gain), 
sulphonylureas 
• Insulin 
Taken from Haslam et al. Lancet; 2005. 
 
 
1.1.2.3. Measurement of obesity 
The absolute measurement of body fat is difficult and no single method is readily 
available for routine clinical use (Pi-Sunyer 2000). Chemical analysis of fat content in 
animals are commonly performed while in humans were only performed in cadavers 
during the 60’s (Widdowson 1965, Sheng et al 1979) and the outcome from these 
studies have shown a wide range of body fat content among different individuals. The 
underwater weighing (UWW) method or hydrodensitometry is based on the assumption 
that the body is divided into two compartments: adipose tissue and lean body mass 
(muscle and bone); as fat has a lower density under water therefore the body weighs 
less. Apart from being tedious and labor intensive, this method does not take into 
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account the high density of bones and muscles in athletes, which leads to body fat 
percentage underestimation, while the body fat of an osteoporotic patient may be 
overestimated (Haslam et al 2005). In contrast dual-energy X-ray absorptiometry 
(DEXA) is based on a three compartment measurement: bones, muscles and fat tissues. 
This technique is based on the assumption that bone content is directly proportional to 
the amount of X-ray absorbed by the bone being studied. In a comparative study, DEXA 
and UWW provided complementary information with DEXA values being lower. Thus, we 
used absolute measurement of body fat in mice for accurate results (Chapter 3). 
Nevertheless, DEXA is becoming the new gold standard method for human studies 
(Kennedy et al 2009).  
 
Relative fat measurement assessing total body weight and body mass index (BMI) is 
also used in human studies. Obesity has conventionally been determined as a 20% 
increment in weight relative to subjects having the lowest death rate, matched for age 
and gender (Laquatra et al 2000, Longe et al 2006). This has been replaced completely 
by BMI, which is the ratio of weight (kg) to squared height (m2). WHO now adopts and 
accepts a BMI of 25 kg/m2 or more as overweight and obese when the BMI reaches 30 
kg/m2 or more (WHO 2000). This is relevant as dyslipidemia gradually develop when 
BMI increases above 21 kg/m2, and when BMI reaches 30 kg/m2, small and dense LDL 
particle increases the risk of coronary heart disease by 3.6-fold (Willett et al 1995). In 
addition, associated low levels of HDL cholesterol and high concentrations of TG further 
and independently aggravate CVD risk (Wannamethee et al 1998).  
 
More importantly the pattern of fat distribution will lower the threshold at which CVD 
of obesity starts. Obese patients with metabolic syndrome have an apple-like abdominal 
obesity and are at earlier risk for diabetes, than pear-shaped fat distributed around hips 
and thighs (Lebovitz et al 2003). The former is associated with cytokines release into the 
circulation, such as the tumor necrosis factor, leading to a proinflammatory state, insulin 
resistance and CVD (Lebovitz et al 2003). From the 52 countries participating in the 
INTER-HEART study (Yusuf et al 2004) the predictive ability of the waist/hip ratio (WHR) 
is superior compared to waist circumference (WC) or BMI, although WC measurements 
are more practical. In contrast, in another study BMI and WC were found to perform 
better over WHR for fatness assessments (Neovius et al 2005). A waist circumference of 
greater than 102 cm in men and 88 cm in women is an established risk factor for insulin 
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resistance, diabetes mellitus and CVD (Pi-Sunyer 2000). However the most accurate 
way to measure abdominal obesity is by magnetic resonance imaging (MRI) or 
computed tomography (CT) scanning, although both are expensive for routine clinical 
use (Pi-Sunyer 2000).  
 
In summary, the surge in obesity rate continues to threaten our communities and 
economies. Health problem related to obesity does not depend on the absolute amount 
of fat but rather the distribution. Quantitatively and qualitatively ways to measure fat is 
required to prevent chronic disease and/or detect side effect of treatment modalities. The 
development of safe PCSK9 inhibitors must not lead to abdominal obesity as a side 
effect, as this would defeat their purpose, since abdominal obesity may lead to an 
increased incidence of atherosclerosis and CVD. 
 
1.1.3. Atherosclerosis  
The true incidence of atherosclerosis is impossible to compute, because it remains 
asymptomatic for years before a person starts to complain. Therefore the frequency of 
clinical manifestations of atherosclerosis is used instead. The process of atherosclerosis 
begins during childhood with the development of fatty streaks (McGill et al 2000). These 
lesions can be found in the aorta shortly after birth and appear in increasing numbers 
between 8 and 18 years (Guardamagna et al 2009). But serious lesions begin to develop 
in high risk groups when an individual reaches the fourth and fifth decades of life 
(Goldstein et al 1987). 
 
However, we must make a distinction between arteriosclerosis and atherosclerosis. 
Arteriosclerosis occurs in smooth muscle cell layer of the tunica media, while the 
atherosclerosis occurs in sub-endothelial layer of the tunica intima (Porter et al 2004). 
Arteriosclerosis refers to vessel hardening or loss of elasticity and occurs diffusely in 
medium size arteries. It does not cause narrowing of the lumen. Arteriosclerosis occurs 
as a consequence of aging, diabetes, metabolic bone diseases, renal failure, 
hypertension and osteoporosis (Table III). Atherosclerosis on the other hand refers to 
vessel thickening due to plaque build up. It occurs as patches at sites of low shear stress 
and causes narrowing of the lumen. Atherosclerosis occurs as a consequence of 
hypercholesterolemia, diabetes, hyperhomocysteinemia and excessive smoking Table 
III illustrates the main differences between arteriosclerosis and atherosclerosis.  
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Table III. Arteriosclerosis   vs.  Atherosclerosis  
Arteriosclerosis Atherosclerosis 
Vessel hardening (loss of elasticity) Vessel thickening (plaque build up) 
Diffuse (medium size arteries) Patchy (low shear stress sites) 
Does not cause narrowing of the lumen Cause narrowing of the lumen 
Age, diabetics, metabolic bone disease, 
renal failure, hypertension and 
osteoporosis. 
Age, hypercholesterolemia, 
hyperhomocysteinemia and smoking. 
Summarized and taken from wikipedia. 2011 
 
1.1.3.1. The pathogenesis of atherosclerosis  
Atherosclerosis is characterized by foam cells and plaque formation that potentially 
may erupt and cause thrombosis. This may lead to blood obstruction in vital organs, like 
the heart or the brain. Nevertheless, atherosclerotic plaques may also regress in 
response to statins and become less susceptible to eruption, but the associated calcific 
lesions may not regress (Chan KL et al 2010). The oxidized LDL particles that find their 
way into the sub-endothelium space as a result of endothelium dysfunction are engulfed 
by macrophages. Foam cell are then formed and subsequently die to give fatty streaks 
and plaques. The plaque formation process stimulates the cells of vascular bed to 
differentiate and produce substances that accumulate in the sub-endothelium. Notably, 
calcium deposition and calcified connective tissue start to form. The inner layer of the 
arterial wall thickens, the artery diameter shrinks and the blood flow starts to be 
compromised.  
 
1.1.3.2. The progression of arterial calcification 
Aortic calcification is complex and the exact mechanism is unknown, but damage to 
the endothelium may be the initial hit. Damage can be due to high cholesterol, blood 
glucose, blood pressure or cigarette smoking (Demer et al 2008). The role of 
triglycerides in aortic calcification is unclear (Awan et al 2008). High levels of 
triglycerides are often associated with diabetes, obesity, and low levels of high-density 
lipoprotein cholesterol, features of the metabolic syndrome and another cause of calcific 
atherosclerosis (Ellison et al 2005). The latter are all modifiable, while heredity, sex and 
age are not. Some people experience calcification in their 50’s or 60’s, others have rapid 
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progressive atherosclerosis and/or calcification during their 20’s, e.g., when they have a 
genetic predisposition as in FH (Alrasadi et al 2009).  
 
From over 30 prospective clinical studies, arterial calcification was associated with 
most conventional cardiovascular risk factors and was deemed an independent risk 
factor for CVD (Rennenberg et al 2009). Arterial calcification is a cause of morbidity and 
mortality at any site: coronary arteries, peripheral arteries or aortic wall (Budoff et al 
2007, Blacher et al 2001, Awan et al 2008). Plaque instability is a feature of calcified 
plaque, inducing mechanical failure leading to plaque rupture (Hoshino et al 2009). 
Aortic rigidity also leads to systolic hypertension, myocardial enlargement, myocardial 
infarction, heart failure, aortic aneurysm, ischemic limbs and death (Shao et al 2010, 
Awan et al 2008, London et al 2002, Budoff et al 2007). Calcification occurs most 
commonly in renal failure (Moe et al 2004), followed by uncontrolled diabetes, 
aggressive smoking and hypercholesterolemic disorders (Shao et al 2010). However, 
more extensive lethal calcification occurs in rare metabolic mutations as in homozygous 
deficiency of the enzyme nucleotide pyrophosphatase 1, a potent calcification inhibitor 
leading to infantile CVD (Rutsch et al 2008). Patients with fibrodysplasia ossificans 
progressiva, caused by a mutation in the BMP type-I receptors, are characterized by 
ectopic bone formation in muscles and soft-tissues that are mediated by cells of vascular 
origin (Hegyi et al 2003). FH patients develop premature severe calcific aortopathy and 
valvulopathy, which underscores the role of hyperlipidemia and/or the LDLR-deficiency. 
Correction of the hyperlipidemia does not alter the progression of calcification (Awan et 
al 2008). Furthermore a gene-dose effect of aortic calcification was observed in FH 
independent of cholesterol levels (Alrasadi et al 2009). Similarly loss of other genes like 
the NOTCH gene may lead to aortic valve calcification in susceptible individuals by 
favoring osteoblast differentiation (O’Brien 2006). 
 
For over one hundred years, pathologists observed extra skeletal bone formation in a 
vascular bed (Bunting et al 1906, Virchow et al 1863). Later when the field of lipids 
expanded, calcified plaques were thought to occur passively in degenerative tissues. In 
the last few years, numerous mechanisms have been implicated in arterial calcification 
(Budoff et al 2007). Atheromatous calcification is currently considered a highly regulated 
process involving cellular components and regulatory factors (Wallin et al 2001, O'Brien 
2006). Whether atherosclerosis activates the calcification machinery, or calcification 
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leads to the hardening of the vessels is still an enigma. Likely both occur in parallel, but 
one mechanism might be the initiating event (Table IV). In the case of kidney disease, 
mineral imbalance is an important contributor since the calcium, phosphate and 
calcification inhibitors and stimulators are dysregulated once kidney function becomes 
abnormal (Touyz et al 2009). 
 
Arterial calcification is divided into two main histological categories: Mönckeberg and 
atheromatous calcification (Table IV): 
 
Mönckeberg type of calcification is a cellular independent and dependent process. 
Amorphous mineral is believed to be deposited first, leading to the formation of 
amorphous calcified matrix that may be fueled by losing inhibitory calcification factors or 
acquiring pro-calcification factors (Sage et al 2010). Mineral imbalance is caused by 
excess calcium, phosphate and parathyroid hormone elevation. This induces a cellular 
differentiation process leading to chondro-osseous formation and eventual bone 
formation in the arterial wall (Cecilia et al 2004). 
 
Atheromatous type of calcification is classically related to hypercholesterolemia 
(oxidized LDL), excess glucose, high homocysteine (Van Campenhout et al 2009) or 
oxidative stress (smoking) (Marangon et al 1998, Ker-Zabel et al 2003). Endothelial 
dysfunction arises from any of the previously mentioned insults. Scavenger cells infiltrate 
the site of insult and plaque is formed in a patchy manner, leading to inflammation that 
drives local cellular differentiation to an osteoblast-like phenotype, which later may form 
bone in the arterial wall.  
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Table IV: Associated calcification mechanisms* 
Arteriosclerosis Atherosclerosis 
Mönckeberg calciphylaxis Atheromatous calcification 
Smooth muscle layer (Tunica media) Sub-endothelium layer (Tunica intima) 
Diffuse (circumferential around elastic 
laminae) 
Patchy (within atheromatous plaques in 
Type I collagen) 
Cellular independent and dependent 
process 
Cellular dependent process 
Amorphous matrix formation followed by 
 chondro-osseous formation 
Osteochondrogenesis followed by 
mineralization 
Mineral imbalance related mechanism: 
• Calcium, phosphate and 
pyrophosphate imbalance. 
• Losing inhibitory factors. 
• Acquiring promoting factors. 
• Cellular differentiation. 
Metabolic excess related mechanism: 
• Endothelial dysfunction. 
• Oxidative stress and inflammation. 
• Macrophage infiltration. 
• Plaque formation. 
• Cellular differentiation. 
* Taken from Sage et al. Nature review; 2010. 
 
 
Thus, in both types of calcification, differentiation of bone-like cells ultimately 
appears to occur, producing a calcified matrix. Although the initiating events may differ, 
ultimately the calcifications many mechanisms may overlap. Furthermore, both types of 
calcification can simultaneously occur in the same individual and/or the same vascular 
bed (Sage et al 2010). 
 
Arterial calcification can also be re-classified in four categories based on their underlying 
mechanisms: 1) imbalance in mineral metabolism (Cecilia et al 2004, Dellegrottaglie et 
al 2006), 2) loss of calcification inhibitory factors (Weissen-Plenz et al 2008), 3) gain of 
calcification activator factors (Touyz et al 2008)  (Table V), and 4) chondro-osteogenic 
cell differentiation (Shao et al 2006).  
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Table V: Factors that affects vascular calcification* 
Activators Inhibitors 
• Inorganic phosphates 
• TGFb1 
• 25-hydroxycholesterol 
• cAMP 
• MAP kinase 
• Acetylated LDL 
• Homocysteine 
• Glucose 
• Endothelin-1 
• Elastin degradation products 
• Pit-1 
• Leptin 
• Reactive oxygen species 
• BMP2-Msx2-Wnt 
• Wnt–β-catenin–lrP-5 
• Vitamin D 
• Collagen type I 
• Alkaline phosphatase 
• Pyrophosphate 
• Statins 
• N-3 fatty acids 
• Tropoelastin 
• Bisphosphonates 
• Matrix Gla Protein 
• Osteopontin 
• Osteoprotegrin 
• NPP-1 via PPi 
• Fetuin-A (Ahsg) 
• Smad6 
• Klotho 
• Carbonic anhydrase-2 
• Calcimimetics 
• BMP-7 
• CaR 
• Vitamin K 
• Estrogen 
* Taken from Touyz et al. Cardiovasc Res; 2009.  
 
The pathophysiology of arterial calcification in FH is likely to be different from the 
vascular calcification observed in patients with renal disease treated with hemodialysis, 
where the imbalance in calcium and phosphate homeostasis, parathyroid hormone and 
vitamin D may contribute to the differentiation of local vascular cells to an osteoblast-like 
phenotype (Johnson et al 2006). Imbalance in mineral metabolism was not found in 
aortic calcification of FH patients, as addressed in our recent publication (Awan et al 
2010).  
Cells in the arterial walls of patients with either type of vascular calcification share 
many features with osteoblasts, including expression of bone morphogenic protein 2 
(BMP2), core binding factor α1 (Cbfa1) and osterix, which have been isolated from 
calcified arterial wall lesions (Figure 7). This osteoblast-like phenotype of cells in the 
vessel wall is further supported by the prevalence of aortic valve calcification seen in 
individuals harboring a mutation in the NOTCH gene leading to the activation of the 
Runx2/Cbfa1 pathway (O’Brien 2006), one of two known pathways involved in 
osteoblast formation, with the other being the Wnt/Lrp5/β-catenin pathway (O’Brien 
2006, Shao et al 2010). 
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Figure 7. Potential interplay of lipids and inflammation with genetics in the 
pathogenesis of calcification. Oxidized lipids, may induce osteoblastic 
differentiation of fibroblasts by upregulating expression of BMP2, which activates 
the Wnt/Lrp5/B-catenin pathway through upregulation of the transcription factor, 
Msx2. In addition, multiple cytokines, including TNF-, IL-1, and RANKL, may also 
promote calcification by activation of this pathway. Hypercholesterolemia is also 
associated with activation of the Runx2/Cbfa1 pathway in aortic valve disease. 
Increased phosphate (PO4) levels, as are seen in chronic kidney disease, might 
promote valve calcification through upregulation of Runx2/Cbfa1. Genetic factors 
may interact to further promote osteoblastic differentiation. NOTCH1 is shown as 
one example of how a genetic abnormality might contribute to both valvular 
morphological abnormalities and valvular calcification. Taken from O'Brien. 
Arterioscler Thromb Vasc Biol; 2006. 
 
Similarly, other mutations associated with FH may affect these pathways (Figure 7). 
One possible mechanism is that similar signaling dysregulation in one pathway may be 
involved with LDLR−/− cells causing vascular calcification, as observed in Ldlr−/−, 
APOB100/100 mice. Controversy about the origin of these osteoblast-like cells, i.e. whether 
they represent phenotypic changes in vascular smooth muscle cells, pericytes or 
differentiated mesenchymal stem cells is unresolved. Nevertheless, the pathophysiology 
of arterial calcifications in FH may well be caused by an interplayed between 
atherogenic factors and underlined genetic predisposition.  
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Furthermore, it would be of interest to test the remaining mechanisms of arterial 
calcification in an animal model. Before embarking on approaches to examine 
mechanisms, a sensitive examination method to measure calcification in soft tissue must 
be established in the same animal model that resembles human disease. This will 
validate any claims of cure or attenuation of arterial calcification. 
 
1.1.3.3. Measurement of arterial calcification 
For many years, physicians have made the diagnosis of atherosclerotic calcification 
during physical examination by simple means of palpation of hard arteries, auscultation 
by stethoscope for carotid bruits and more recently and accurately by Doppler 
examination. Vascular calcification in humans can be also detected on a standard x-ray 
or quantified more precisely by CT scan (Iijima et al 2011; Alrasadi et al 2009). 
Computed tomography or CT scan enabled physicians to measure the degree of 
calcified atherosclerotic plaques in the aorta and coronary arteries (APPENDIX I). This 
step is critical in patients at risk of aortic calcification undergoing major heart or aortic 
surgery to prevent intra-operative complications (Awan et al 2008). 
 
Although conventional histology allows quantification of calcification, this 
occasionally leads to destruction of sample integrity and reduces in vivo structural 
preservation. In the proceeding chapter (CHAPTER 2), we applied micro-CT, a 
miniaturized version of CT, to detect and quantify aortic calcification in mice with a 
resolution of 5-20 µm. The micro-CT used (SkyScan) was initially developed to evaluate 
bone density in human teeth and skeletal parts of rodents. Therefore the apparatus 
imposed technical challenges to adopt a soft tissue mouse aorta to fit a small slot 
designed for holding small hard objects. 
 
In summary, atherosclerosis and arterial calcification are complex processes. They 
require good novel tools to elucidate the cause of progression and evaluate potential 
therapeutic approaches. Similar to LDLR mutations, PCSK9 gain-of-function mutations 
carry at risk of atherosclerosis and arterial calcification. The understanding of PCSK9 
biology is advancing each day and will benefit from innovative research tools. 
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2. The Proprotein Convertase Family 
Proprotein convertases (PCs) are calcium-dependent serine endoproteases that play 
a key role in the post-translational processing of precursors of bioactive peptides. Many 
precursors of neuropeptides, hormones, enzymes, receptors or growth factors are 
synthesized as inactive precursors (prohormones) and are activated by proteolytic 
cleavage; this catalytic function is carried out by specific PCs (Seidah et al 1999, Fugère 
et al 2002).  
Mammalian PCs belong to a family of 9 subtilisin/kexin proteases (Seidah et al 
2008). The genes coding for PCs are designated by the letters PCSK and they are 
numbered from 1 to 9. PCSKs products are critically involved in various physiological 
processes depending on their protease activities resulting in activation/inactivation 
events, some of which could lead to cardiovascular homeostasis (Seidah et al 2007, Tall 
2006) (Figure 8A).  
 
 
Figure 8. The Proprotein Convertases Family. (A) Classification of proteases of 
the genome with emphasis on the PCs. (B) Schematic representation of the 
structure of bacterial subtilisin, yeast kexin and the mammalian PCs. The different 
domains and active site residues are shown. Taken and modified from Seidah et al. 
2006 and 2007. 
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All PCSK products have an N-terminal signal peptide, a pro-segment domain, a 
catalytic domain and a P domain (Seidah et al 2008) (Figure 8B). The catalytic domains 
are highly conserved between many species. The 80-90 amino acids length pro-
segment first is cleaved by an auto-catalytic mechanism in the endoplasmic reticulum 
(ER). The pro-segment acts both as an intramolecular chaperone to promote proper 
folding and as a competitive inhibitor of PCs function; this seems to prevent PCs from 
being accidentally activated during synthesis. The second round of cleavage occurs after 
a second set of basic amino acid residues in the pro-segment releasing it from the 
catalytic domain leading to activation of the PCs (Bergeron et al 2000, Seidah et al 
2008). 
 
2.1. Mammalian proprotein convertases in lipid metabolism 
The first seven members of the mammalian PCs are similar in that they cleave 
protein precursors at basic amino acids. Out of these seven PCs, the fifth member, 
proprotein convertase subtilisin/kexin 5 (PCSK5), has relevance to lipid metabolism. 
Variation in the coding sequence of PCSK5 gene affects the HDL cholesterol levels as 
shown in a recent study (Iatan et al 2009). HDL cholesterol is inversely correlated to 
cardiovascular disease. This is achieved by the direct inactivation of endothelial lipase 
by PCSK5. PCSK5 also indirectly cleave and activate angiopoetin-like protein 3, a 
natural inhibitor of endothelial lipase and, consequently, affects atherosclerotic CVD risk 
(Iatan et al 2009) (Figure 8B). 
 
The eighth member, PCSK8 also known as subtilisin kexin isozyme-1 (SKI-1) or site 
1 protease (S1P), is known to cleave membrane-bound transcription factors, including 
sterol regulatory element binding proteins (SREBP-1 and -2), in the luminal domain of 
the Golgi apparatus, which when further cleaved by S2P, results in the release of their 
DNA-binding domain in absence of sterols. After cleavage, the cytosolic N-terminal 
domain becomes water soluble and translocates to the nucleus. This activated SREBP 
then binds to specific sterol regulatory element DNA sequences, thus upregulating the 
synthesis of enzymes involved in sterol/lipid biosynthesis. Sterols inhibit the cleavage of 
additional SREBP through a negative feedback loop, and thus synthesis of additional 
sterols is turned down (Horton et al 2002). Therefore, SREBPs are named master 
regulators of lipid homeostasis (Eberlé et al 2004) (Figure 9).  
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The ninth member, PCSK9 formerly named NARC1 (Neural Apoptosis Regulated 
Convertase-1) (Seidah et al 2003) is involved in the post-translational regulation of the 
protein levels of the LDLR, affecting circulating cholesterol. 
 
  
 
Figure 9. SREBPs are master regulators of lipid homeostasis. Sterol regulatory 
element binding protein (SREBP) are activators of the complete program of cholesterol 
and fatty acid synthesis in the liver. Taken from Horton et al. J Clin In vest; 2002. 
 
 
2.1.1. PCSK9 domains and crystal structure 
The human 25-kb PCSK9 gene lies on the short arm of chromosome 1, and 
comprises 12 exons and 11 introns (Seidah et al 2007, Davignon et al 2010). After its 
identification in 2003, the crystal structure of PCSK9 was revealed in 2007 (Cunningham 
et al 2007, Piper et al 2007) (Figure 10B).  The PCSK9 692 amino acid product has an 
N-terminal signal peptide, a prosegment domain, a catalytic domain, a hinge region (of 
unknown function) and a C-terminal and Cys-His rich domain. Unlike the first seven 
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basic PCs it has no P domain (Seidah et al 2003, Naureckiene et al 2003). Sequence 
analysis of the catalytic domain indicates that three conserved residues; Asp186, His226, 
and Ser386 comprise the active catalytic center (Figure 10A). The PCSK9 S1 pocket that 
recognizes the cleavage P1 site of its prosegment is shallower compared to other 
subtilases. This is due to the replacement of one glycine residue on the side of the S1 
pocket by an Alanine raising the pocket floor (Piper et al 2007). In all domains, gain or a 
loss of function mutations have been reported (Davignon et al 2010) and summarized in 
Figure 11. Even variations in the PCSK9 hinge region (e.g. R434W) have mysteriously 
resulted in a loss of function, with a lower level of circulating cholesterol (Dubuc et al 
2010) (Figure 10). Interestingly, these highly conserved amino acids differ when 
compared to other subtilases. 
 
 
Figure 10. PCSK9 domains, biology and crystal structure. (A) PCSK9 is a 
protease that is synthesized as an enzyme precursor. Following synthesis, 
PCSK9 undergoes autocatalytic cleavage, which is required for secretion from the 
cell. Although cleaved, the pro-segment and catalytic domains of PCSK9 remain 
together. (B) When LDL cholesterol binds to the LDL receptor, they are both 
internalized into endosomes and upon binding to PCSK9; the LDL receptor is 
redirected for lysosomal degradation and prevented from recycling to the cell 
surface. 1 and 2 represent PCSK9 endogenous and exogenous pathways. Taken 
from Horton et al. J Lipid Res, Vol. 50, S172-S177, April 2009. 
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2.1.2. PCSK9 site of synthesis and distribution 
PCSK9 is synthesized as a precursor, like all members of the PCs family, that 
undergoes autocatalytic cleavage of its N-terminal pro-segment in the endoplasmic 
reticulum, a step required for its exit from this compartment and its efficient secretion. 
Different from other secreted PCs, PCSK9 remains associated with its pro-segment 
(Figure 10B). PCSK9 is expressed in many tissues, but mainly in liver, small intestine, 
and kidney (Seidah et al 2003, Zaid et al 2008). Depending on the technique used for 
detection, levels are also high in the pancreas (Seidah et al 2003, Mbikay et al 2010). 
For this reason some investigators have already started to examine the role of PCSK9 in 
many organs at different pathological conditions. Recent data indicate an important role 
of PCSK9 in liver regeneration (Zaid et al 2008). Another important role for PCSK9 is the 
prevention of lipotoxicity in pancreatic cell by limiting the LDLR action to internalize 
excessive lipids inside β-cells. In theory the loss of this protection may lead to lipotoxicity 
induced diabetes when a PCSK9 inhibiter is given (Cnop et al 2002, Roehrich et al 2003, 
Ishikawa et al 2008, Mbikay et al 2010). In light of all of these strong biological 
involvements, we investigated the role of PCSK9 in vascular calcification, fat distribution 
and deposition in mice (CHAPTER 2). 
 
2.1.3. PCSK9 natural substrate and activity 
Unlike other proprotein convertases, PCSK9 has no known substrate other than itself 
(Zaid et al 2008). PCSK9 binds to the EGF-like domain A of the LDLR (Cunningham 
2007) and is thought to target the LDLR to the endosomal/lysosomal pathway (Maxwell 
et al 2004, Benjannet et al 2004). The low pH in these compartments facilitates PCSK9 
binding to the LDLR (Fisher et al 2007).  There are two proposed sites where PCSK9 
can come in close proximity to the LDLR: in the TGN (intracellular route) (Nassoury et al 
2007, Poirier et al 2009) and on the cell surface of hepatocytes (extracellular route) 
(Lagace et al 2006) (Figure 10). Interestingly other LDLR family members like VLDLR 
and apoER2 also share homology in the EGF-like domain (Figure 1).  Because human 
PCSK9 targets ex vivo human VLDLR (Poirier et al 2008) and binds in vitro mouse 
VLDLR (Shan et al 2008), PCSK9 has the potential to target human VLDLR in vivo. In 
theory that would affect tissues in which VLDLR is abundant, i.e.; muscle and adipose. 
Muscles usually burns fat while adipose tend to store energy as fat droplets for later use 
by the body. Therefore it would of interest to examine the VLDLR as a potential in vivo 
target of PCSK9 in adipose tissue (CHAPTER 3). 
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2.1.4. PCSK9 and lipid metabolism 
PCSK9 favors the post-translational degradation of the LDLR by an unclear 
mechanism. By modulating the level of LDLR it acts as a regulatory checkpoint. 
Induction of PCSK9 levels by the statins will decrease LDL-C statin-lowering potential in 
human. That is to say that statins would have had a higher capacity to decrease LDL-C if 
it was not for the concomitant rise in PCSK9 level following statin administration. 
Moreover it was shown that PCSK9 transcription could be suppressed by fasting and 
induced by insulin, likely by activating liver X receptor and SREBP-1c (Costet et al 
2005).  
 
Family studies of coronary heart disease patients led to the mapping of PCSK9 gene 
to familial hypercholesterolemia (Abifadel et al 2003). This was supported by gain-of-
function mutations exhibiting high serum levels of LDL-C, while loss-of-function 
mutations are known to lower serum levels of LDL-C and protect from coronary heart 
disease (Cohen et al 2005). Likewise Pcsk9 in KO mice exhibit higher LDLR expression 
in the liver leading to the decrease in serum cholesterol. In contrast, the overexpression 
of Pcsk9 reduces LDLR levels, resulting in increased serum cholesterol levels (Maxwell 
et al 2004). 
 
Until now, one compound heterozygote loss of function mutation and one 
homozygote mutation were reported in humans (Zhao 2006 et al, Hooper et al 2007). 
One of the individuals harboring these mutations, a 32-year-old fertile apparently healthy 
female, had been described with undetectable circulating PCSK9 resulting in a strong 
reduction of LDL-C by 86% (Zhao et al 2006). Lowering cholesterol earlier in life is 
believed to produce greater impact on preventing CVD. This has been shown in a study 
of natural PCSK9 loss-of-function mutations associated with 28 percent reduction in 
mean LDL-C and 88 percent reduction in the risk for cardiac events (Cohen et al 2006). 
A list of mutations discovered in PCSK9 is presented in Figure 11 (Davignon et al 2010). 
 
 
 
 
 
 
                                                                                                                                                                  32  
 
Figure 11. The PCSK9 protein and mutations influencing plasma LDL-C. The 
PCSK9 primary structure and domains – SP: signal peptide, pro: pro-segment 
domain, catalytic:  catalytic domain and CHRD: Cysteine-Histidine rich domain. Key 
residues, aspartic acid (D), histidine (H), asparagine (N) and serine (S) are depicted. 
PCSK9 becomes active after auto-catalytic cleavage of the pro-segment. The 
position and the amino acid substitutions of the mutations that are associated with 
high LDL-C levels are shown above the protein, those that are associated with a 
reduced plasma LDL-C are shown below. Taken from Davignon et al. Curr 
Atheroscler Rep; 2010. 
 
 
Therefore, an inhibitor of PCSK9 is thought to be beneficial. To further investigate 
the effect of PCSK9 inhibition, scientists have generated total and conditional knockout 
of the Pcsk9 gene (Pcsk9 –/–) in mice on a C57BL/6 background, as previously described 
(Zaid et al 2008). These models have allowed us to advance our understanding of 
PCSK9 role in different organs and different metabolic conditions. In vivo studies have 
shown that conditional knockout in livers, extreme metabolic conditions like partial 
hepatectomy results in delayed liver regeneration and formation of liver lesions (Zaid et 
al 2008). Fortunately, when a high-cholesterol diet was supplemented after partial 
hepatectomy, the lesions where absent, which indicates an indirect role of PCSK9 in 
hepatic regeneration capacity. Furthermore in vivo studies had shown that PCSK9 
deficiency was associated with a 2-fold decrease in postprandial triglyceride levels, 
suggesting enhanced triglyceride clearance (Le May et al 2009) and a role of PCSK9 in 
TG metabolism. 
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2.1.5. PCSK9 as a potential therapeutic target  
As previously mentioned, PCSK9 favors the post-translational degradation of the 
LDLR, therefore decreasing its capacity to lower LDL-C. PCSK9 therefore acts as 
regulatory checkpoint for the LDLR. This makes PCSK9 a promising therapeutic target 
(Lilly et al 2007, Seidah et al 2007, 2009, Lambert et al 2006, Lopez 2008, Hedrick et al 
2009) and several companies have developed various approaches to inhibit PCSK9: 1) 
poly- and monoclonal antibodies targeted against PCSK9 (Chan JC et al 2010), 2) 
antisense small interfering RNA (siRNA) (Frank-Kamenetsky et al 2008) or locked 
nucleic acid (LNA) (Gupta et al 2010), 3) small-molecule inhibitors. Phase one clinical 
trials based on siRNA targeting PCSK9 have unfortunately suffered from adverse clinical 
off target effects. In contrast, the development of conventional small-molecule 
therapeutics to inhibit PCSK9 continues to present challenges (Hedrick et al 2009) 
(Figure 12). The method that will move to clinically application will depend on long-term 
safety, cost and ease of administration (Davignon et al 2010). For instance, Chan et al 
reports remarkable cholesterol lowering in monkeys with the use of a single injection of 
monoclonal antibody (mAb) against PCSK9. This effect on plasma cholesterol levels 
occurs after the infusion of humanized mAbs that bind to PCSK9 and inhibits binding to 
LDLR. A single injection reduces the LDL-C levels by 80 % for more than a week. In the 
same study, they show a synergistic effect of mAb and statins on the induction of LDLR 
levels.  Thus, this suggests that inhibiting PCSK9 in combination with statin would lead 
to more lowering effects on hypercholesterolemia (Chan JC 2010). Furthermore on the 
same line, phase one trial in human have already started by many pharmaceutical 
companies like Regeneron© .Some safety data from the use of their antibody have been 
released in an abstract in a resent international conference (Swergold et al 2010). In this 
report they claim an LDL-C reduction in health human volunteers reaching 60% and 
lasting for 30 days with no significant elevation in liver transaminases.   Additionally, 
locked nucleic acid antisense oligonucleotides (LNA ASO) that targets both human and 
mouse PCSK9 have similarly shown great efficiency in reducing PCSK9 (Gupta et al 
2010) (Figure 12). 
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Figure 12. Novel pharmacology approaches to treat hypercholesterolemia. (1) 
PCSK9 undergoes autocatalytic cleavage. Although cleaved, the two domains of PCSK9 
remain together. When LDL cholesterol binds to the LDL receptor, they are both 
internalized into the cell. (2a) If the cholesterol-bound LDLR is also bound to PCSK9, the 
LDL receptor is redirected for lysosomal degradation and prevented from recycling to the 
cell surface. (2b) If an internalized LDL receptor is not bound to PCSK9, the receptor is 
recycled to the cell surface, where it continues to remove LDL-C from circulation. A 
number of companies are developing compounds that stifle PCSK9 activity, either by 
blocking synthesis of the protein or by inhibiting PCSK9 binding to the LDLR. Taken from 
Lou et al. Sci BX; 2009. 
 
 
Although protein and small peptide injection are not particularly attractive for lifelong 
treatment, such treatments would likely be accepted by patients suffering side effects 
from current anti-lipidemic agents or high risk patients striving to achieve lower LDL-C 
levels. For example, heterozygous familial hypercholesterolemia patients, for whom 
initial LDL-C levels starts around three times that of the general population, are unable to 
achieve even a 50 percent reduction with available oral agents and often require may 
LDL apheresis, a form of dialysis to eliminate the LDL-C from the blood (Rader et al 
2003). 
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Despite its apparent safety, there are concerns about the idea of inhibiting PCSK9, 
since we know little about its entire biological function. Therefore, before we start to 
assess their clinical implications or embark on more clinical trials, careful experiments 
must be conducted to evaluate the consequences of inhibiting PCSK9.  Animal modeling 
is a proven strategy to screen new drug modality. Of course, unanticipated and 
disqualifying toxic side effects (e.g; Ab-PCSK9 immune complexes) can only be ruled 
out in large-scale, multicenter trials. Therefore, much remains to be done to bring any of 
these PCSK9 inhibitors to the bedside (Steinberg et al 2009) (Figure 12).  
 
3. Hypothesis and objectives 
 
 3.1. First hypothesis and objectives 
Although severe atherosclerosis should be the primary target for most interventions 
to prevent mortality from CAD, secondary targets in surviving patient should shift to 
arterial calcification to lessen the morbidity of this disease as our population grows older 
and develop extensive arterial calcifications. These secondary interventions will help to 
lessen the burden of expensive procedures and lengthy hospitalizations. In previous 
studies, we have shown that FH patients carrying null mutation for the LDLR are at 
higher risk of premature aortic calcifications (APPENDIX I) and the degree of 
atherosclerotic calcification was not correlated with cholesterol levels, neither initially nor 
on treatment (Awan et al 2008). Calcification rather depends on the degree of LDLR 
deficiency (homozygote vs. heterozygote) (Alrasadi et al 2009). To date no information is 
available on other gene mutations that lead to FH and whether they are similarly 
affected. Therefore, it was interesting to document the occurrence and degree of aortic 
calcification associated with transgenic mice overexpressing PCSK9 (mimicking LDLR-
deficiency), which reflects “gain-of-function mutations” in human. Thus, we 
hypothesized that the degree of the LDLR deficiency (whether by knocking the 
Ldlr gene or by overexpression Pcsk9 gene to over degrade the LDLR) will have a 
major impact on the degree of aortic calcification and will be independent of diet. 
To perform this in a methodological way we first replicated the findings obtained in 
human investigations (images and histology) (APPENDIX I) in our LDLR knockout mice 
and measure aortic calcifications by this sensitive method. We then will apply the same 
methodology to transgenic mice overexpressing PCSK9 as compared to wild-type and 
Ldlr knockout mice in an age- and diet-dependent manner. 
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3.2. Second hypothesis and objectives 
In our laboratory, we recently noticed that lacking PCSK9 mice tend to accumulate 
visceral fat (APPENDIX II). It is possible to imagine that PCSK9 inhibition could lead to 
fat tissue dysfunction and insulin resistance in mice and humans. In vivo studies had 
shown that PCSK9 deficiency was associated with a 2-fold decrease in postprandial 
triglyceride levels, suggesting enhanced triglyceride clearance (Le May et al 2009). No 
report to date has systematically addressed the mechanism by which PCSK9 influences 
fat tissue metabolism. Thus, we hypothesized that VLDLR, a closely related family 
member of the LDLR abundant in adipose tissue, could be a target of PCSK9. 
Accordingly, it was shown that PCSK9 enhances VLDLR degradation ex vivo (Poirier et 
al 2008). We proposed to study, the functional aspect of adipose tissue in mice lacking 
Pcsk9 gene with (single knockout) or without Ldlr (double knockout) gene to establish a 
direct in vivo role for PCSK9. By immunohistochemistry, we will show that VLDLR levels 
were affected in the adipose tissue and that this will cause a direct impact on fat 
metabolism.  Additional, we investigated in vivo and ex vivo the metabolism of FFA 
uptake and TG synthesis in the adipose tissue of PCSK9 KO mice.  
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CHAPTER 2:  
PCSK9 AND AORTIC WALL CALCIFICATION 
 
4. Foreword: Article 1 
From our previous work, we noticed that FH patients present with premature 
aortic calcification (APPENDIX I). A gene-dosage effect of the LDLR has been 
correlated with aortic calcification. Despite cholesterol lowering modalities, the 
progression of the disease seem to be independent from levels of circulating cholesterol. 
In addition, our evaluation of calcium homeostasis and bone density could not explain 
this finding. Therefore in the following study we examine this phenomenon in a 
laboratory animal model to assess the degree of LDLR-deficiency in relation to the 
extent of calcium deposition at sites of vascular injury in the presence or absence of a 
Western diet. We applied an animal model for aortic calcification using genetically 
modified mice. Therefore we studied Ldlr-/- and PCSK9 Tg mice using a sensitive imaging 
technique. Extensive calcifications were observed in old Ldlr-/- chow-fed mice. In WT 
mice fed a Western diet, similar cholesterol levels to Ldlr-/- chow-fed mice were 
achieved, however no significant calcification was observed. The magnitude of 
cholesterol level and calcification degree in PCSK9 Tg mice was between WT and Ldlr-/- 
mice but more toward WT, suggesting that LDLR availability may be required for 
preventing extensive calcification. This article also reports a novel use of micro-CT to 
quantify calcification in mice. 
 
Animal dissections, sample treatments, image analyses, compiling data, statistical 
analysis, as well as manuscript writing and editing, were conducted by Zuhier 
Awan (first author) and Maxime Denis (second author). 
 
* Article submitted to Arteriosclerosis on March 31st, 2011, 
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4.1.1. Abstract 
Objective: Patients with Familial hypercholesterolemia (FH) due to LDLR mutations 
suffer premature aortic calcification, an effect that is age- and gene dosage-dependent 
and unaltered to cholesterol reduction later in life. To better understand this process, we 
examined murine models. Methods: We compared chow fed Ldlr-/- mice to controls at 6, 
12 and 18 months and on a Western diet (WD) at 6 months. Additionally, we compared 
controls to Ldlr-/- mice and transgenic (Tg) mice overexpressing PCSK9 protein (PCSK9 
Tg), which promotes LDLR degradation. Aortas were perfused-fixed, embedded in 
paraffin, and sections were stained with alizarin red. We used micro-computerized 
tomography (micro-CT) to quantify vascular calcification. Results: Ldlr-/- mice develop 
calcification in the ascending, transverse aorta and neck vessels with a distribution 
similar to that of human. Histology confirmed that the calcification were predominantly 
sub-intimal. Calcification was most prominent in 18-month-old Ldlr-/- mice fed a chow diet 
and in 6-month-old Ldlr-/- mice fed a WD. Interestingly; PCSK9 Tg mice fed a WD develop 
aortic calcification. Conclusions: The two mouse models develop aortic calcification in 
an age- and diet-dependent manner. Further analysis of these mouse models of aortic 
calcification with the micro-CT imaging may provide a better understanding of the links 
between FH and arterial calcification. 
 
Word count: 5351 
Word count of Abstract: 199 
Figures and Tables: 4 Figures, 2 Tables and 1 Supplementary video  
Key Words: Familial Hypercholesterolemia, LDLR, PCSK9, Aortic Calcification and 
Micro-Computed Tomography  
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4.1.2. Introduction 
 
Patients with homozygous familial hypercholesterolemia (FH) due to mutations of 
the low-density lipoprotein receptor (LDLR) gene have severe coronary artery disease 
(CAD) manifesting in childhood or young teens and later developing into severe aortic 
stenosis. The advent of extracorporeal LDL removal techniques in the 1980s coupled 
with pharmacological therapy has allowed homozygous FH patients to reach adulthood. 
The development of calcific aortic stenosis in homozygous FH is a condition well known 
to clinicians. Several case series in the surgical literature have described extensive 
calcification of the ascending aorta in homozygous FH, a condition often referred to as 
“porcelain aorta” (1). This creates a surgical challenge during aortic valve replacement, 
requiring the simultaneous replacement of the ascending aorta using a Cabrol or Bental 
procedure (1). By using computerized tomography (CT) scan of the thoraco-abdominal 
aorta, we have previously shown that homozygous FH patients have extensive, 
premature calcification of the entire aorta, with an aortic calcium score (AoCS) reaching 
5,000 Agatston units by the second decade of life (2). In heterozygous FH, age-
dependent calcification also occurs, but 20 years later (3). In contrast, in subjects without 
mutations at the LDLR locus, such vascular calcification is not encountered until the 7th 
decade of life.  
The mechanism of arterial calcification in FH is not well understood. Clinical 
observations in homozygous FH suggest that the calcification process continues 
unchecked. Despite the reduction of total and LDL-cholesterol (LDL-C) levels by 
conventional therapy and the reduction in the progression of CAD, severe calcific aortic 
stenosis develops and often warrants valve replacement. Aortic wall calcification also 
has untoward effects on cardiovascular health, including higher systolic blood pressure, 
aneurysm and rupture of the aorta (4). Furthermore, calcified lesions in the aorta have 
the potential to: 1) impinge on coronary arteries causing myocardial ischemia (5); 2) 
contribute to ischemic stroke and peripheral vascular disease as a result of dislodged 
lesions (6, 7, 8); and 3) complicate angiography during catheterization and surgical 
procedures (1). In addition, calcification within the aorta can create a technical artifact 
when attempting to determine both carotid stenosis by Doppler sonography (9, 10) and 
bone mineral densitometry by DEXA scan (11, 12). 
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To better understand the role of the Ldlr gene and LDLR protein in the process of 
FH arterial and valvular calcification, we sought to characterize mouse models that 
potentially recapitulate this phenotype. Since mice and humans share many important 
physiological characteristics, we believed mouse models would provide a suitable 
counterpart to study the pathogenesis of human arterial calcification, malformation, and 
the mineralization of the aortic valve. Herein, we demonstrate that inactivation of the Ldlr 
gene or degradation of the LDLR protein in vivo results in premature aortic calcification 
as seen in FH. Degradation of the LDLR protein was achieved by over-expressing the 
Pcsk9 gene that encodes the PCSK9 protein, the ninth member of the proprotein 
convertase family.  
Lakoski et al reported that a 100 ng/ml increment in plasma PCSK9 level was 
associated with a 4.5 mg/dL increase in plasma LDL-C concentration in women and 3.2 
mg/dL increase in LDL-C in men. (13). PCSK9 exerts this effect on cholesterol 
metabolism through post-translational downregulation of the LDLR (14). PCSK9 binds to 
the epidermal growth factor motif of the LDLR and the complex is endocytosed and 
targeted for intracellular degradation (14, 15). We have previously postulated that the 
LDLR may play a key role in vascular calcification based on observational studies in 
patients with homozygous and heterozygous FH due to LDLR defects (2). Therefore, we 
wanted to use an independent mouse model to examine the role of the LDLR on aortic 
calcification. In addition, as the high expression transgenic mice resemble gain-of-
function mutations in PCSK9 and causes autosomal dominant hypercholesterolemia 
(16), we also presently tested the hypothesis that if LDLR-deficiency was necessary in 
initiating aortic calcification; therefore calcification should then be observed in PCSK9 Tg 
mice on either a chow (regular diet) or high-fat Western Diet (WD).  
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4.1.3. Material and methods 
 
Animal protocol 
Our maintained colony of Ldlr-/- mice (C57BL/6J back-ground; stock 002529) (n=30) 
were purchased from The Jackson Laboratories (Bar Harbor, ME, USA). PCSK9 Tg mice 
overexpressed mouse PCSK9 under the control of ApoE promoter (17) and were since 
backcrossed to C57BL/6J for 10 generations. Suitable age- and diet-matched C57BL/6J 
wild-type (WT) mice (n=45) were used as controls for both genotypes. Mice were fed 
either a normal chow diet (2018 Teklad Global) or a WD diet when indicated (Harlan 
Teklad # TD 88137) from weaning until sacrifice. Mice were kept in a pathogen free 
facility under 12 hour light/dark cycles. Mice were fasted for 3 hours prior to being 
sacrificed and 86 adult mice were used in this study. All procedures were approved by 
the IRCM animal care committee. 
 
Aorta isolation and fixation 
Aortic isolation was carried out as previously published (18), with some modifications. In 
brief, mice were anesthetized with isoflurane at a rate of 2% in 1 L of oxygen. Blood was 
removed via intracardiac puncture through an intact diaphragm and the circulatory 
system was flushed with 5-6 mL of phosphate buffered saline (PBS) through the left 
ventricle at a pump rate of 0.4 mL per minute. To keep the aortic wall from collapsing, 
the aorta was perfused and fixed in situ with 4% phosphate-buffered paraformaldehyde 
(PBP). The aorta was extracted in bulk by opening the chest wall and gently lifting the 
heart and excising posterior to the thoracic aortic and abdominal aorta until the renal 
artery. The apex of the extracted aorta was excised and the aortic tissue was fixed ex 
vivo in 4% PBP at 4°C for 24-48 hours. After fixation, microscopic fine dissection was 
performed and each intact aorta was embedded in a single paraffin block. 
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Tissue sampling and processing 
As mentioned previously, blood was collected from mice at the induction of anesthesia 
by puncture of the left ventricle, and then transferred immediately to heparin anti-
coagulated tubes on ice. Whole blood was used to measure glucose via a commercial 
glucometer (Bayer Diabetes Care, USA). Plasma was separated by centrifugation (20 
minutes at 850g and 4°C) and kept at –20°C until assayed. Total cholesterol and 
triglyceride levels were measured by Infinity Total Cholesterol (Thermo Fisher Scientific 
Inc, MA, USA) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan) kits, 
respectively, and according to the manufacturer's recommendations. 
 
Calcification and lesion analysis 
After dissection, the entire aorta was exposed to digital imaging capture. Aortas were 
then embedded in paraffin blocks for calcium measurement. The calcium content of the 
entire aorta and aortic valve was determined by digital X-ray quantification on a micro 
computed tomography (micro-CT) scanner (Skyscan-1072, TomoNT version 3N.5, 
Belgium) adopting the following parameters: 40 kV voltage; 248 A current; 50 X zoom; 
5.63 m pixel size; no filter applied; 0.9 rotation step, 2.2 second between frames at a 10 
micron slice thickness. The calcium score was determined using dedicated software 
(CTAn v.1.8.1.2). Aortic calcification score (AoCS) was expressed as the ratio of 
calcified volume (mm3) over aorta volume (mm3) multiplied by 100 and expressed in 
arbitrary units (A.U.). While being rotated on a vertical axis, a three-dimensional (3D) 
reconstruction image and video were produced using commercial software (ANT 3D 
creator v.2.4 and NRecon v.1.4.4) to further analyze the aorta and aortic valve 
(Supplemental video image online). The blocks were then sectioned and stained with 
Alizarin red S solution (25 mg/l alizarin red S in 1% potassium hydroxide) to confirm 
calcium deposition in regions corresponding to calcified segments on micro-CT (Figure 
1).  
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4.1.4. Results   
 
Micro-computed tomography characterizes aortic calcification 
Vascular calcification in humans can be detected on a standard x-ray or quantified more 
precisely by CT scan (19, 3). In the present study, we applied micro-CT, a miniaturized 
version, to detect and quantify aortic calcification in mice with a resolution of 5-20 μm. 
Although conventional histology allows quantification of calcification, this occasionally 
leads to destruction of sample integrity and reduces in vivo structural preservation. To 
test the superiority of micro-CT scanning, murine aortas were imbedded in paraffin 
blocks to retain anatomical position while calcium content was determined. We found 
that micro-CT was rapid and allowed a 3D-virtual visualization of the aorta for better 
lesion quantification and characterization. Thus, Ldlr-/- mice develop calcification in the 
ascending, lower part of the transverse aorta and neck vessels with a distribution 
strikingly similar to that observed in humans. The aorta was subsequently sectioned and 
stained with alizarin red to confirm calcification (Figure 1A). Representative X-ray scans 
and 3D-reconstructions are shown in Figure 1B and 1C. The AoCS was determined from 
histological and 2D and 3D micro-CT analysis. Consistent with previous reports, there 
was a good agreement of calcium volume estimates between histological and micro-CT 
analyses (data not shown). 
 
Age-dependent aortic calcification in Ldlr-/- mice on chow diet  
Characteristics of the mice are shown in Table 1. As shown in previous studies (20), 
body mass remained relatively stable in Ldlr-/- mice (34, 38 and 39 g) compared to that of 
control mice that increased with time (36, 44 and 50 g at ages 6, 12 and 18 months, 
respectively). Body mass differences between Ldlr-/- and control mice reached statistical 
significance only at 18-months (P-value < 0.05). There were no significant differences 
between liver sizes (% of body weight) or glucose levels between groups except at 12 
months where Ldlr-/- mice are significantly higher (Table 1). Total cholesterol levels were 
increased with age in both Ldlr-/- and WT mice. As expected, circulating plasma 
cholesterol and triglyceride (TG) levels were 3-fold higher in Ldlr-/- mice relative to WT 
mice (P-values ≤ 0.001) consistent with previous reports (21). Fed a chow diet, Ldlr-/- 
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mice developed spontaneous calcification that increased with age, with a statistically 9-
fold increase of the AoCS between 12 and 18 moths (P-values = 0.02) (Table 1, Figure 
2D), recapitulating the age effect seen in human FH (3). WT mice did not develop 
significant calcification at any age. Analysis of 3D images of aortas from 18-month-old 
Ldlr-/- mice identified the areas of low shear stress as being the most calcified (Figure 1). 
Alizarin red staining of paraffin sections at the level of the aortic root and carotid artery 
confirmed the presence of calcium (Figure 2). As shown in Figure 2, vascular 
calcification was predominantly observed in the sub-endothelial, sub-intimal space and 
was associated with atherosclerotic plaques. This is similar to our previous report in 
human FH subjects that underwent aortic valve replacement and aortic surgery (2). 
These data suggest that LDLR deficiency and/or elevated total cholesterol and/or TG 
levels initiate aortic calcification, and that the severity of calcification increases with age. 
 
Accelerated aortic calcification in LDLR-deficient mice fed a WD  
Ldlr-/- mice fed a WD for 6 months maintained a lower body mass (37 versus 49 g for 
controls; P-value ≤ 0.001) and lower liver size (% of body weight) (5.8  versus 10.3 g for 
controls, P-value ≤ 0.001). However, glucose levels were not affected (Table 2). As 
expected, circulating cholesterol and TG levels were the highest in Ldlr-/- mice 
maintained on a WD, with average levels of 2248±862 mg/dL and 509±118 mg/dL, 
respectively (Table 2). Circulating cholesterol levels were also significantly increased in 
WT mice fed a WD as compared to age-matched WT mice fed a normal chow diet 
(509±118 mg/dL versus 101±9 mg/dl; P-value ≤ 0.01). By micro-CT quantification, Ldlr-/- 
mice of 6 months of age were found to develop extensive aortic calcification when fed a 
WD (Figure 3A and 3B). The degree and pattern of calcification were similar to that of 
18-month-old Ldlr-/- mice fed a chow diet, with an AoCS 300-fold higher (Figure 3C) than 
for age-matched controls (3.01±2.0 versus 0.01±0.0 A.U.; P-value <0.001). This 
indicates that a WD accelerates arterial calcification. 
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Elevated cholesterol alone was not sufficient to produce severe aortic 
calcification 
WT mice fed a WD for 12 months had a lower AoCS than Ldlr-/- mice of the same age 
maintained on a normal chow diet (0.75±1.1 versus 0.02±0.0 A.U.) (Table 1 and 2), even 
though they exhibited higher total cholesterol levels (440±151 mg/dL versus 316±65 
mg/dL for age-matched Ldlr-/- mice fed a chow diet). This suggests that elevated 
cholesterol levels alone do not result in severe aortic calcification. Taken together, these 
data suggest that absence of the LDLR is the major contributor to aortic calcification, 
and that the process is accelerated in the presence of a WD (Figure 4A).  
 
Aortic calcification in Pcsk9 high expression transgenic mice  
Using the calcification rate of Ldlr-/- mice as an indicator, we chose to study two time 
points in PCSK9 Tg mice where calcification should be present if LDLR-deficiency does 
impact the process of calcification: 18 months on a chow diet and 12 months on a WD. 
Unlike Ldlr-/- mice, 18-month-old PCSK9 Tg mice exhibited a body mass and liver size 
similar to that of WT mice (Table 1). Glucose levels were also similar. Although lower 
than in Ldlr-/- mice, total cholesterol and TG levels found in PCSK9 Tg mice were higher 
than controls. Of the two mice that were assisted by micro-CT, only one developed 
calcification making the difference non-significant in compare to WT, and therefore future 
analysis was conducted in PCSK9 Tg mice at 12 months of age fed a WD (Table 2 and 
Figure 3D-F). When fed a WD for 12 months, PCSK9 Tg mice had equivalent total body 
and liver weight to that of control mice (Table 2). Their blood sugar levels were also 
similar. Cholesterol levels of PCSK9 Tg mice were significantly higher than that of age-
matched controls (1043±236 versus 440±151 mg/dL), and TG levels were also 
significantly increased relative to controls (Table 2). However, cholesterol levels of 
PCSK9 Tg mice (1043±236 mg/dL) were still lower than those obtained in 6-month-old 
Ldlr-/- mice fed a WD (2248±862 mg/dl). Similar to Ldlr-/- mice, 12-month-old PCSK9 Tg 
mice fed a WD had aortic calcification, with AoCS increased significantly in compare to 
age-matched controls on a WD (1.69±1.2 versus 0.02±0.00 A.U.; PCSK9 Tg versus 
controls, P-value <0.01) and exhibited an intermediate calcification level with an AoCS 
85-fold higher than in controls (Figure 3D, 3E and 3F). 
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4.1.5. Discussion 
Arterial calcification in human is associated with considerable mortality and 
morbidity. The pathophysiology of arterial calcification is poorly understood and has 
been the subject of recent reviews (22, 23). Once thought to be a passive process 
related to age, arterial calcifications are now believed to be due to a complex interplay 
between vascular injury, inflammation, and osteogenesis (24, 25). Therefore arterial 
calcification can be classified into four categories based on machinery: 1) imbalance in 
mineral metabolism (26, 27), 2) loss of calcification inhibitory factors (28), 3) gain of 
calcification activator factors (29), and 4) chondro-osteogenic cell differentiation (30). 
Imbalance in mineral metabolism occurs most commonly in renal failure patients (31). 
Renal calcification resembles the most extensive calcification in a chronic disease 
followed by diabetes, heavy smoking and hypercholesterolemia (25). Rare deficiencies 
in the nucleotide pyrophosphates 1 enzyme, a potent inhibitor of calcification leads to 
lethal infantile calcification and cardiovascular diseases in homozygous patients (32). 
Similarly, loss of both calcification inhibitors osteopontin and matrix Gla protein leads to 
spontaneous and extensive arterial calcification in a double knockout mouse model (33). 
Additionally, patients with fibrodysplasia ossificans progressiva caused by a mutation in 
the BMP type I receptor are characterized by earlier onset of ectopic bone formation in 
muscles and soft-tissues that are mediated by cells of vascular origin (34). In FH 
patients, neither the onset nor the site of calcification fits the phenotype of genetic 
inhibitors or activators of calcification. Furthermore the pathophysiology of arterial 
calcifications in FH is likely to be different from that of renal disease treated with 
hemodialysis, and whose balances in phosphate and calcium homeostasis, parathyroid 
hormone and vitamin D are significantly altered, as addressed in our recent publication 
(11). Therefore, it is of interest to examine alternative mechanisms in animal models.  
Using mice either lacking totally (Ldlr-/-) or exhibiting lower LDLR protein levels, 
(PCSK9 Tg) we provided evidence for the existence of a correlation between LDLR 
levels and vascular calcification. Relative to controls, Ldlr-/- mice on any diet exhibited 
significantly elevated cholesterol, triglyceride levels, and accelerated aortic calcification 
as quantified by micro-CT. Conversely, only PCSK9 Tg mice fed WD, exhibited 
significant aortic calcification although at a lesser extent than Ldlr-/- mice fed WD for a 
shorter period (Table 2). In contrast, calcification was undetectable in WT mice on chow 
and there was insignificant calcification when hypercholesterolemia was induced by WD 
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(Figure 4A). Thus, LDLR-deficiency increases aortic calcification independently of 
cholesterol levels, as observed in human studies (2). Since calcification is significantly 
milder in PCSK9 Tg mice than in Ldlr-/- mice. We propose that the decreased severity of 
calcification in PCSK9 Tg is due to both the less severe hyperlipidemia and to the 
residual LDLR proteins, not affected by PCSK9 (17). This is consistent with previous 
observations made between men carrying a null-mutation of the LDLR gene (the French 
Canadian deletion >15 Kb) that includes the promoter region, exon 1 and part of intron 
1) and low LDLR activity due to missense mutations (3). Therefore, PCSK9 Tg mice may 
represent the intermediate levels of calcification observed in heterozygote FH patients. 
Nevertheless, because 12 month-old WT mice start to develop mild calcification on WD, 
hypercholesterolemia must have been the initiating factor whereas the absence of LDLR 
significantly enhances the progression of calcification. 
We have observed previously that arterial calcifications in surgical specimens of 
homozygous FH patients undergoing aortic valve and ascending aorta replacements are 
predominantly sub-intimal (2), unlike renal failure patients (35, 36, 37). The mouse 
model presented herein reproduces the same histological changes observed in humans 
(Figure 1 and Figure 2). Arterial calcification within the intimal layer (as compared to 
medial calcification associated with renal failure) is a common feature of atherosclerosis 
in animal models and in human disease. Various cell types therefore may participate in 
this process. Macrophages, mast cells, and vascular smooth muscle cells (SMC) found 
in plaques are postulated to be the primary cells involved in atherosclerotic intimal 
calcification, with a smaller contribution from SMC (38). Alternatively, calcification may 
be promoted by mesenchymal stem cells which arise from various cellular elements in 
the vascular wall and which can mimic the repertoire of bone marrow stem cells in their 
capacity to differentiate into chondrocytic and osteoblastic cells (39). Bone-marrow 
derived osteoblast-like cells have also been suggested to participate in the development 
of vascular calcification (40).  
The process of cell-induced calcification involves the activation of fibroblasts and 
myofibroblasts through a variety of stimuli including oxidized LDL, angiotensin II, and 
cytokines (TNFα, RANKL, and IL-1β) secreted by macrophages. In turn, these events 
trigger the bone morphogenic protein 2 activation of MX-2 and the Wnt/Lrp5/beta catenin 
pathway, as well as the Runx2 mediated activation of osteoblast function. The Ldlr-/- 
mouse model fed high-fat diet has been used previously to study aortic valve 
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calcification (41). In this model, the authors concluded that TNFα induced the Msx2-Wnt 
pathway to promote vascular calcification. Another model of aortic stenosis uses old (17-
25 months) Ldlr-/- ApoB100/100 hypercholesterolemic mice; here aortic stenosis and 
calcifications were demonstrated by echocardiography, hemodynamic measurements 
and histology (42). However, aortic calcification in this case may be critically dependent 
on multiple metabolic abnormalities (elevated oxidized lipoproteins, diabetes, obesity, 
inflammation), and not necessarily on the absence of the LDLR protein. Neither of these 
previous studies addressed the potential role of the LDLR in progression of aortic wall 
calcification. In the present model, the mice were neither diabetic nor obese (Table 1, 2). 
Thus, the pathogenesis of hypercholesterolemia-induced aortic calcifications in the 
obese, hyperlipidemic, diabetic mice does not apply here.  
 
4.1.6. Clinical perspective 
Studying vascular calcification mechanisms may lead also to a better 
understanding of the development of calcific aortic stenosis, a common disease in older 
individuals for which, presently, the only option is valve replacement (surgical or 
transcutaneous). Lowering of plasma cholesterol with statins has been shown to inhibit 
hypercholesterolemia-induced calcification of the aortic valve in animal models via the 
LRP5/β-catenin pathway (43). However, clinical trials testing the ability of statins to 
reduce the progression of calcific aortic stenosis have not been met with success (44). In 
our experience in patients with homozygous and heterozygous FH due to mutations in 
the LDLR, despite normalization of plasma cholesterol levels, vascular calcification 
proceeds in an age- and gene-dosage fashion, irrespective of cholesterol levels (2,3). 
Therefore, it remains to be determined whether long-term statin use and/or lifelong 
LDLR reduction is associated with an altered prevalence of aortic stenosis. With the use 
of a representative animal model of FH, such as Ldlr-/- or PCSK9 Tg mice, the ability of 
combination therapy using anti-inflammatory agents, hormonal modulation, calcium 
channel blockers, and/or chelating agents to attenuate arterial calcification can be 
explored further.  
In conclusion, the results of the current study suggest that aortic calcification is 
associated with age and LDLR function, and is accelerated by a WD. We provide a 
mouse model of extensive vascular calcification that replicates the disease observed in 
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humans. Furthermore, we provide a precise and quantifiable method of measuring aortic 
calcification in mice using micro-CT. The implications of these findings are two-fold. 
First, we replicate human premature aortic calcification in two animal models resembling 
absolute LDLR deficiency and low LDLR availability. Second, similar to humans, we 
developed a novel technique to reliably assess the site and extent of aortic calcification 
digitally in these animals. This should now facilitate studies on both the pathophysiology 
of arterial calcification and the efficacy of different treatment modalities. 
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4.1.9. Tables: 
 
 
 
 
Table 1. Attributes of WT, Ldlr -/- and Tg (Pcsk9) mice on regular (chow) diet
Age (months) 6 12 18 
Number (total) n=10 n=10 n=10 n=6 n=10 n=9 n=2 
Gene WT Ldlr -/- WT Ldlr -/- WT Ldlr -/- Tg 
Number n=10 n=10 n=10 n=6 n=10 n=6 n=2 
Body weight (g) 36±5 34±2 44±8 38±10 50±5 39±12* 36±2* 
Liver (% of weight) 3.9±0.5 4.1±0.3 4.5±0.7 5.0±1.2 5.4±1.2 5.4±1.4 4.6±1.0 
Cholesterol (mM) 101±9 375±38*** 151±22 316±65*** 199±43 561±247*** 213±16 
Triglycerides (mM) 40±10 122±47*** 30±9 126±17*** 20±7 125±77*** 50±3*** 
Number n=3 n=5 n=4 n=6 n=4 n=5 n=2 
AoCS (A.U.) 0.00±0.00 0.00±0.00 0.00±0.00 0.75±1.10 0.00±0.00 6.73±4.86* 0.01±0.01 
  
 
 
 
 
Table 2. Attributes of WT, Ldlr -/- and Tg (Pcsk9) mice on western diet
Age (months) 6 12 
Number (total) n=10 n=8 n=5 n=9 
Gene WT Ldlr -/- WT Tg            
Number n=10 n=8 n=5 n=6 
Body weight (g) 49±3 37±8*** 57±7 56±16 
Liver (% of weight) 10.3±1.1 5.8±1.0*** 8.7±1.7 7.5±1.0 
Cholesterol (mM) 509±118 2248±862*** 440±151 1043±236 *** 
Triglycerides (mM) 34±10.3 574±285*** 35±19 119±39** 
Number n=9 n=6 n=5 n=9 
AoCS (A.U.) 0.01±0.04 3.01±2.05** 0.02±0.04 1.69±1.2* 
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4.1.10. Figure legends: 
 
 
 
 
 
Figure 1: Measurement of aortic calcification in mice by micro-computed 
tomography. A: Digital image of an atherosclerotic aorta after fine dissection (top panel) 
and paraffin section symbolized by the red lane and stained with alizarin red to confirm 
calcification (bottom panel). B: Corresponding digital X-ray images from top panel in (A) 
and a cross-section symbolized by the red line. C: Corresponding 3D reconstructed 
images. 
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Figure 2: Age-dependent aortic calcification in Ldlr-/- mice. Aortic calcification in Ldlr-
/- mice fed a regular chow diet at 6 (A), 12 (B) and 18 (C) months of age. For each age 
group, representative images of aortas after fine dissection (top left panel), 3D 
reconstructions of calcification (bottom left panel), and alizarin red stained sections of 
calcified lesions (top and bottom right panels) are shown. Arrows indicate site of 
calcification. (D) Age-dependence of the AoCS in Ldlr-/- versus age-matched WT mice.  
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Figure 3: Aortic calcification in Ldlr-/- and PCSK9 Tg mice on a WD. Aortic 
calcification in WT (A) and PCSK9 Tg mice (B) mice at 12 months of age on a WD. A 
representative image of an aorta after fine dissection is presented (top panel), and a 
corresponding 3D reconstructed image (bottom panel). Arrows indicate site of 
calcification. (C) AoCS histogram of WT mice compared to PCSK9 Tg mice on WD at 12 
months of age. Aortic calcification in WT (D) and PCSK9 Tg mice (E) at 12 months of age 
on a WD for comparison purpose, again presented as a digital image and a 
corresponding 3D micro-CT reconstructed image showing the extensive calcification (F) 
AoCS histogram of WT mice compared to Ldlr-/- mice on WD at 6 months of age. 
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Figure 4: The degree of AoCS in relation to circulating cholesterol. (A) AoCS 
overlying cholesterol histogram comparing WT on WD to age-matched Ldlr-/- mice on 
normal chow diet at ages 6 and 12 month. (B) AoCS overlying cholesterol histogram 
comparing WT, PCSK9 Tg and Ldlr-/- mice at ages 18 months on a chow diet.  
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CHAPTER 3:  
PCSK9 AND FAT METABOLISM 
 
5. Foreword: Article 2  
In the following chapter, we will focus on the effect of PCSK9 deficiency on fat 
metabolism. In this article, we compared adipose tissue of WT mice versus Pcsk9-/- mice 
in the presence or absence of LDLR. By dissecting visceral adipose we confirmed that at 
6 months of age, Pcsk9-/- mice accumulate 80% more visceral adipose tissue than WT 
mice in an LDLR-independent manner (APPENDIX II). In vivo and ex vivo functional 
analyses of adipose tissue demonstrated an increased fatty acid uptake and a higher 
triglyceride synthesis in Pcsk9-/- males and females. In addition, immunohistochemistry 
data illustrated clearly an increase in VLDLR surface availability in adipose tissue. Since 
VLDLR is a close member of LDLR family, absence of PCSK9-mediated degradation of 
VLDLR is likely the mechanism of VLDLR accumulation in Pcsk9-/- mice. Finally PCSK9 
liver specific knock-out and knock-in mice were used to illustrate that the sole source of 
circulatory PCSK9 is of hepatic origin. These sets of experiments are an attempt to 
predict the impact of drugs targeting PCSK9 as a method of lowering cholesterol and the 
safety profile surrounding this method.  
 
All experiments, animal sampling, data compiling and analyzing as well as parts of 
the manuscript preparation was conducted by Anna Roubtsova (first author) and 
Zuhier Awan (second author), with the exception of the in vivo and ex vivo.  
 
*Article published in Arterioscler Thromb Vasc Biol following peer review (Jan 27, 
2011) 
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5.1.1. Abstract 
 
Objective- Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation 
of the low-density lipoprotein receptor (LDLR), and its gene is the third locus implicated 
in familial hypercholesterolemia. Herein, we investigated the role of PCSK9 in adipose 
tissue metabolism. 
Methods and Results- At 6 months of age, Pcsk9-/- mice accumulated ~80% more 
visceral adipose tissue than wild type mice. This was associated with adipocyte 
hypertrophy and increased in vivo fatty acid uptake and ex vivo triglyceride synthesis. 
Moreover, adipocyte hypertrophy was also observed in Pcsk9-/- Ldlr-/- mice, indicating 
that the LDLR is not implicated. Rather, we show here by immunohistochemistry that 
Pcsk9-/- males and females exhibit 4- and ~40-fold higher cell surface levels of very- low-
density lipoprotein receptor (VLDLR) in perigonadal depots, respectively. Expression of 
PCSK9 in the liver of Pcsk9-/- females re-established both circulating PCSK9 and normal 
VLDLR levels. In contrast, specific inactivation of PCSK9 in the liver of wild type females 
led to ~50-fold higher levels of perigonadal VLDLR. 
Conclusions- In vivo, endogenous PCSK9 regulates VLDLR protein levels in adipose 
tissue. This regulation is achieved by circulating PCSK9 that entirely originates from the 
liver. PCSK9 is thus pivotal in fat metabolism: it maintains high circulating cholesterol 
levels via hepatic LDLR degradation, but also limits visceral adipogenesis likely via 
adipose VLDLR regulation. 
 
Key words: PCSK9, VLDL receptor, adipose tissue metabolism, fatty acid uptake, 
proprotein convertase 
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5.1.2. Introduction 
PCSK9 is the ninth member of the family of proprotein convertases (PCs; encoded 
by the genes PCSK1 to PCSK9) that share identity with subtilisin and kexin1. The first 8 
members of the family cleave protein precursors of hormones, growth factors, receptors 
and transmembrane transcription factors that transit through or reside in the secretory 
pathway2. In contrast, PCSK9 has no known substrates but itself. It undergoes an 
autocatalytic cleavage of its N-terminal prosegment1, 3, which remains trapped in the 
catalytic pocket4. 
PCSK9 shortens the half-life of the LDLR5, a process independent of its catalytic 
activity6. Gain-of-function mutations in the PCSK9 gene lead to autosomal dominant 
hypercholesterolemia7, as do mutations in the LDLR and APOB genes. Other PCSK9 
mutations or polymorphisms responsible for loss of function result in 
hypocholesterolemia8. 
PCSK9 is highly expressed in the liver1, where it binds the LDLR and promotes its 
internalization and degradation in endosomal/lysosomal compartments5. Thus, mice 
lacking PCSK9 (Pcsk9-/-) exhibit a 2 to 3-fold increase of the LDLR protein in liver 
homogenates, and a substantial accumulation of the receptor at the hepatocyte cell 
surface9, 10. This leads to hypocholesterolemia (-40%), with a ~5-fold drop in LDL-
cholesterol levels. In humans, where 70% of cholesterol is associated with LDLs, versus 
only 30% in mice, the hypocholesterolemia due to PCSK9-deficiency is even more 
dramatic. Two women lacking functional PCSK9 exhibited LDL-cholesterol levels of ~0.4 
mM (15 mg/dL)11, 12. PCSK9 is now considered as a promising target to treat 
hypercholesterolemia and prevent coronary heart disease. 
Human PCSK9 is abundant in plasma13 and analysis of mice that lack PCSK9 
specifically in liver revealed that circulating PCSK9 originates primarily from this tissue10. 
Whether physiological levels of circulating PCSK9 affect the LDLR protein levels in 
peripheral tissues, independent of its local expression, is yet to be demonstrated. 
Another issue is the ability of PCSK9 to target other receptors. The major binding site 
of PCSK9 to the LDLR involves its catalytic domain, which interacts with EGF-A, one of 
three EGF-like repeats present in the extracellular domain of the LDLR14. In the LDLR 
family, VLDLR and apoER2 that are the two closest receptors to LDLR also contain an 
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EGF-A repeat that shares ~60% identity with the LDLR one. Ex vivo, the levels of both 
receptors were shown to be efficiently reduced upon PCSK9 overexpression15, 16, 
suggesting that they are in vivo targets of PCSK9. While apoER2 is mainly present in 
brain, VLDLR is highly expressed in heart, skeletal muscle and adipose tissue, where it 
lays at the surface of endothelial cells (for reviews, see17, 18). Different from the LDLR, 
the VLDLR is not regulated by cellular sterols and does not bind LDLs efficiently. It 
rather contributes to the delivery of fatty acids that derive from triglyceride-rich 
lipoproteins to peripheral tissues. It binds apoE-enriched chylomicrons and VLDLs, 
intermediate-density lipoproteins (IDLs), as well as lipoprotein lipase that hydrolyses 
triglycerides into free fatty acids. These interactions are facilitated by heparan sulfate 
proteoglycans that bind lipoproteins and lipoprotein lipase. The latter, like the VLDLR, is 
abundant in adipose tissue, heart and muscle. Finally, free fatty acid internalization is 
facilitated by several proteins, including the translocase FAT/CD3619. 
Although PCSK9 is a key regulator of circulating LDL-cholesterol levels, the question 
of its implication in the regulation of adipogenesis was raised by our seminal observation 
that mice lacking PCSK9 (Pcsk9-/-) accumulated abdominal fat. Furthermore, it has been 
recently reported that postprandial triglyceride levels were 2-fold lower in Pcsk9-/- mice, 
suggesting enhanced clearance20. 
We therefore compared the adipose tissue of WT versus Pcsk9-/- mice. Pcsk9-/- mice 
indeed accumulated more visceral fat in an LDLR-independent manner. In vivo and ex-
vivo functional analyses demonstrated an increased fatty acid uptake and a higher 
triglyceride synthesis in the adipose tissue of Pcsk9-/- males and females. VLDLR protein 
levels were significantly increased in the visceral adipose tissue of Pcsk9-/- mice, 
consistent with the hypothesis that circulating PCSK9 promotes the degradation of the 
VLDLR in this tissue.  
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5.1.3. Methods 
Animals and treatments 
All procedures were approved by the Clinical Research Institute of Montreal animal 
care committee. Pcsk9-/- mice lacking the Pcsk9 proximal promoter and exon 1 were 
described10, and were since backcrossed 10 times to C57BL/6J mice. Ldlr-/- (C57BL/6J 
background; stock 002529) and Vldlr-/- (stock 002207) mice were from The Jackson 
Laboratory. Mice were housed in a specific pathogen-free facility under 12-hour light/12-
hour dark cycles, and fed a normal chow diet (Agribrands, St-Hubert, QC). 
Supplemental Methods available online at http://atvb.ahajournals.org 
 
 
 
5.1.4. Results  
The absence of PCSK9 leads to fat accumulation in perigonadal depots 
In 10 week-old mice fed a chow diet, perigonadal and perirenal masses were 
increased with significant or close to significant P values (P ≤ 0.075) in Pcsk9-/- males 
and Pcsk9-/- females (Figure 1). In 26 week (6 month)-old mice, the increase of 
perigonadal mass reached 77% and 60% in Pcsk9-/- males and females, respectively, 
while the increase of perirenal mass reached 108% and 76%. No significant variations 
were observed in the mass of inguinal, pectoral or brown fat pads (Supplemental Figure 
I), indicating that fat accumulation mainly occurred in visceral adipose tissue. However, 
Pcsk9-/- mice were not prone to obesity. Their body weights only slightly increased, by 4 
to 8%, even when mice were fed a Western diet for 25 weeks after weaning 
(Supplemental Figure II). 
To determine whether fat accumulation was due to adipocyte hypertrophy or 
hyperplasia, paraffin sections of WT and Pcsk9-/- perigonadal adipose tissue were 
analyzed (Figure 2). The average number of adipocytes per mm2 did not differ between 
WT males and females, but was strongly reduced in both Pcsk9-/- males (-46%) and 
females (-53%). With an estimated average adipocyte sectional area of ~4080 μm2 
                                                                                                                                                                  70  
versus 2060 μm2, the Pcsk9-/- adipocytes are estimated to be ~2.8-fold larger than WT 
adipocytes. 
To elucidate whether hypertrophy is due to the loss of PCSK9 in perigonadal fat, we 
evaluated its expression level by quantitative RT-PCR. PCSK9 mRNA was ~160-fold 
less abundant than in the liver (Supplemental Figure), the major expression site of 
PCSK9, thus raising the question of the potential role of circulating PCSK9. 
 
Circulating triglycerides levels are slightly higher in mice lacking PCSK9 
Circulating cholesterol was 32% and 40% lower in Pcsk9-/- males and females, 
respectively, as previously reported for male mice9, 10. Conversely, plasma triglycerides 
were slightly increased in Pcsk9-/- males (+35%; not significant) and females (+46%; P = 
0.03). In agreement, FPLC analyses showed triglyceride enrichment in VLDL fractions in 
both males and females (Supplemental Figure IV). 
 
Dietary lipid uptake is increased in Pcsk9-/- adipose tissue 
To better define the molecular mechanisms leading to fat accumulation, WT and 
Pcsk9-/- mice received a 3H-oleate fat load by gavage after overnight fasting. Plasma 
triglycerides were measured over 3 hours (Supplemental Figure V). Their clearance was 
not significantly affected in Pcsk9-/- mice, although a trend for faster clearance was 
observed in Pcsk9-/- females. After 3 hours, mice were sacrificed to evaluate the 
combined 3H-triacylglycerol and 3H-diacylglycerol content of perigonadal and inguinal 
pads, muscle and liver (Figure 3A). 3H-oleate uptake into tissue represents the overall 
process of lipoprotein hydrolysis (primarily chylomicrons) coupled to fatty acid uptake 
and esterification into triglycerides. In males, 3H-oleate incorporation increased in all 
Pcsk9-/- tissues tested, especially in perigonadal and inguinal pads. In Pcsk9-/- females, 
3H-oleate incorporation increased in perigonadal and inguinal pads, although to a lesser 
extent than in Pcsk9-/- males, while the incorporation in muscle was the same in WT and 
Pcsk9-/- females. Thus, the loss of PCSK9 favors a higher uptake of fatty acids by the 
adipose tissue, in both genders. In contrast to Pcsk9-/- males that exhibited 78% 
increased incorporation in the liver, Pcsk9-/- females showed a 41% lower incorporation. 
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However, because of high variations between mice, P values (0.15 and 0.08) did not 
reach statistical significance (Figure 3A; right panel). 
  
Pcsk9-/- adipose tissue exhibits increased ex vivo triglyceride synthesis 
To evaluate the intrinsic ability of each tissue to synthesize triglycerides directly from 
glucose and fatty acids, pieces of perigonadal and inguinal fat, muscle and liver were 
incubated with 14C-glucose (Figure 3B). Glucose is the precursor of the intracellular 
triglyceride backbone, glycerol-3-phosphate. In these experiments, the contribution of 
lipoprotein binding and lipoprotein lipase-mediated lipolysis of dietary triglycerides is 
bypassed. Triglyceride synthesis was maintained or increased in all Pcsk9-/- tissues 
tested, including male livers in which triglyceride synthesis strongly increased (+118%). 
In contrast, female Pcsk9-/- liver exhibited a significant 53% drop, consistent with the 
41% lower 3H-oleate incorporation observed following the fat load. Altogether, these data 
suggest that PCSK9-deficiency leads to an increased fatty acid uptake that stimulates 
triglyceride synthesis in perigonadal (+80% in males) and inguinal (+93% in Pcsk9-/- 
females; P = 0.1) pads. 
 
Adipocyte hypertrophy in Pcsk9-/- mice is LDLR-independent  
To examine whether adipocyte hypertrophy was dependent on PCSK9-mediated 
LDLR regulation, paraffin sections of perigonadal fat of mice lacking the LDLR and 
having either normal PCSK9 (Ldlr-/-) or null PCSK9 (Ldlr-/- Pcsk9-/-) levels were analyzed 
(Figure 4). In an Ldlr-/- background, the lack of PCSK9 (Ldlr-/- Pcsk9-/-) resulted in 
adipocyte hypertrophy with 39% and 57% fewer adipocytes per mm2 in males and 
females, respectively, similar to the 46% and 53% drops seen in Pcsk9-/- mice (Figure 2). 
Note that in Ldlr-/- perigonadal depots, neither the size of the adipocytes (Figure 4) nor 
PCSK9 expression (Supplemental Figure III) were significantly affected. 
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VLDLR protein levels increase in perigonadal fat in the absence of PCSK9 
Because LDLR regulation by PCSK9 did not seem implicated in the adipose tissue 
phenotype, and as the VLDLR was shown to be targeted by PCSK9 ex vivo15, 16, we 
examined the possibility of its in vivo regulation by PCSK9. 
Western blot analyses were unsuccessful with commercially available antibodies 
and, to our knowledge, adipose VLDLR has never been visualized by Western blot21, 22. 
Paraffin sections of perigonadal depots from 26-week-old mice were therefore analyzed 
by immunohistochemistry (Figure 5). Image analysis (see Methods) revealed that lack of 
PCSK9 led to 4- and 43-fold increase in VLDLR labeling in males and females, 
respectively, revealing a strong VLDLR downregulation exerted by PCSK9 in this tissue, 
especially in females. In the absence of the LDLR, the loss of PCSK9 led to a similar 36-
fold (P < 0.0001) increase in VLDLR labeling in females, but not in males. Note that 
VLDLR was not detected in Vldlr-/- control sections (Supplemental Figure VI). 
VLDLR mRNA levels were assessed in the same tissues by quantitative reverse 
transcription-polymerase chain reaction (Supplemental Figure VII). Although similar in 
the adipose tissue of all male mice, VLDLR mRNA levels in Pcsk9-/- females doubled, a 
difference that cannot account for the 43-fold increase in cell surface VLDLR protein 
levels. In the absence of LDLR, the loss of PCSK9 in females (Ldlr-/- Pcsk9-/-) was 
accompanied by a significant 35% drop in VLDLR mRNA relative to Ldlr-/- females, while 
the surface protein level was increased 36-fold. VLDLR mRNA upregulation is thus not 
responsible for VLDLR protein accumulation at the adipocyte cell surface. In the liver, 
where the VLDLR was not detectable by immunohistochemistry, VLDLR mRNA 
expression was 6 to 27-fold higher in females than in males (P ≤ 0.000005; 
Supplemental Figure VII), depending on the genotype, thus raising the possibility that 
PCSK9 may also affect VLDLR protein levels in female hepatocytes. 
Neither lipoprotein lipase which hydrolyzes triglycerides from triglyceride-rich 
lipoproteins nor CD36 that translocates free fatty acids were affected in perigonadal fat 
pads at the transcriptional level by the loss of PCSK9 and/or LDLR, except in Pcsk9-/- 
females where CD36 mRNA almost doubled (+80%; Supplemental Figure VIII). 
However, this 80% increase may be not essential since CD36 mRNA levels were not 
affected in Pcsk9-/- males, in which fat accumulation and increased 3H-oleate uptake 
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were even more severe than in Pcsk9-/- females, and not affected in the Ldlr-/- 
background. 
 
Circulating PCSK9 regulates adipose VLDLR protein  
The poor expression of PCSK9 in perigonadal depots led us to examine the possible 
role of circulating PCSK9 in VLDLR protein regulation. We took advantage of the liver 
origin of circulating PCSK9. First, we expressed PCSK9 in the liver of Pcsk9-/- mice 
using a transgene that expresses mouse PCSK9 under the control of the apoE promoter 
10 (Pcsk9-/- Tg+/0). This led to a 53-fold reduction of the VLDLR labeling observed in 
Pcsk9-/- females (Figure 6; top panels) and to plasma PCSK9 levels that were ~5-fold 
higher than WT ones (Figure 6; right panel). Second, we compared Pcsk9flox/flox 
(equivalent to WT) mice with littermates carrying a transgene that expresses the Cre 
recombinase under the albumin promoter (Pcsk9flox/flox Alb-cre+/0), and thus lacking 
PCSK9 specifically in hepatocytes10. The relatively low levels of VLDLR protein 
observed in Pcsk9flox/flox females, which do not differ from WT females by their levels of 
circulating PCSK9 (233 versus 238 ng/mL), was dramatically increased (53-fold) when 
PCSK9 was no longer expressed in the liver (Figure 6; lower panels). In the latter mice, 
no circulating PCSK9 was detected by ELISA confirming the unique liver origin of 
PCSK9 and high efficiency of Pcsk9 excision by Cre in hepatocytes10. 
Interestingly, plasma PCSK9 levels were significantly lower (-45%) in Vldlr-/- mice 
(Figure 6, right panel), suggesting that liver PCSK9 is downregulated in the absence of 
the VLDLR. Altogether, these data show that circulating PCSK9 is responsible for the 
reduction of VLDLR protein levels in perigonadal depots. 
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5.1.5. Discussion  
The purpose of our study was to gain insight into the role of PCSK9 in adipose tissue 
metabolism. We show herein that circulating PCSK9 regulates fat accumulation in 
adipocytes. 
Pcsk9-/- mice exhibited larger perigonadal (+70%) and perirenal (+90%) depots than 
WT mice, and the average volume of a perigonadal adipocyte was estimated to increase 
by 2.8-fold. Dietary fat hydrolysis and incorporation was increased in perigonadal and 
inguinal fat (from 1.5 to 2.6-fold) in both Pcsk9-/- males and females, even though the 
inguinal fat mass was moderately increased in 10 week-old mice. In the same tissues, 
the intracellular triglyceride synthesis was maintained or increased, and no major 
changes were observed in WT and Pcsk9-/- fatty acid catabolism evaluated by the 
number of disintegrations per minute (dpm) associated with oxidation products, except 
an 81% increased oxidation in inguinal pads of Pcsk9-/- females (not shown), likely 
leading to an underestimation of the 3H-incorporation in this tissue. 
Although males and females shared the above phenotypes, a striking difference was 
observed in their liver metabolism: 3H-oleate incorporation and triglyceride synthesis 
approximately doubled in the liver of Pcsk9-/- males, but were about 2-fold reduced in the 
liver of Pcsk9-/- females (Figure 3; right panels). In addition, livers from 26 week-old 
Pcsk9-/- mice did not exhibit any steatosis (not shown). This suggests that, following a 
gavage, Pcsk9-/- males have a higher potential to internalize abundant chylomicron 
remnants than Pcsk9-/- females. 
We examined the adipose tissue of Ldlr-/- Pcsk9-/- mice and found that lack of PCSK9 
led to adipocyte hypertrophy independently from the LDLR. This is in agreement with low 
LDLR levels in perigonadal fat, in which LDLR mRNA is ~8-fold lower than in the liver. 
(Supplemental Figure VIII). 
As a candidate target of PCSK9 in fat, the VLDLR presented several key properties. 
It is ~60% identical to LDLR; it was downregulated ex vivo by PCSK915, 16; and it is a 
major lipoprotein receptor in adipose tissue implicated in triglyceride metabolism18. 
When compared to WT mice, Pcsk9-/- males and females had 4- and 43-fold more cell 
surface VLDLR in perigonadal fat, respectively. In Ldlr-/- Pcsk9-/- females, a similar 36-
fold increase was observed. Altogether, these data reveal that PCSK9 exerts, in an 
                                                                                                                                                                  75  
LDLR-independent manner, a strong control on adipocyte VLDLR, especially in females. 
It is tempting to attribute the increased visceral adipogenesis to VLDLR upregulation. In 
agreement with this hypothesis, Vldlr-/- mice were reported to exhibit 15 to 20% lower 
body weights, reduced (-40%) perigonadal fat and adipocyte size, and impaired fatty 
acid uptake22, whereas Pcsk9-/- mice exhibited slightly higher body weights, fat 
accumulation, larger adipocytes and higher fatty acid uptake (this study). Additional 
studies in mice lacking both PCSK9 and VLDLR will be required to verify that the latter 
phenotypes are lost in the absence of the VLDLR.  
Finally, the analysis of different mouse models revealed that circulating, and not 
local, PCSK9 is responsible for adipose VLDLR protein regulation. Expression of PCSK9 
in the liver of Pcsk9-/- mice normalized the VLDLR labeling, while removal of PCSK9 
from the liver of normal mice led to a dramatic increase in adipose VLDLR protein. Thus, 
this study provides the first evidence for an in vivo role of endogenous levels of 
circulating PCSK9. In WT mice, the above data suggest that the latter is responsible for 
the degradation of ~75% and ≥ 95% of the perigonadal surface VLDLR in males and 
females, respectively. 
Curiously, although the absence of PCSK9 led to ~10-fold higher levels of VLDLR in 
female perigonadal pads than in male ones, similar phenotypes in terms of adipocyte 
size and perigonadal mass were observed, whether endogenous levels of circulating 
PCSK9 also target extra-hepatic LDLR remains to be determined. Only huge quantities 
of PCSK9 obtained by injection of purified PCSK9 or adenoviral overexpression were 
reported to reduce LDLR levels in lung, adipose, kidney and/or ileum23.  
Because plasma PCSK9 exclusively originates from the liver, its expression in this 
organ could be pivotal for the coordination between peripheral fatty acid uptake and liver 
lipoprotein uptake, via the regulation of surface levels of VLDLR and LDLR. The function 
of liver PCSK9 may reside in its ability to slow down the catabolism of lipoproteins in a 
coordinated manner, and to maintain proper circulating levels of cholesterol and 
triglycerides. For example, we have previously shown that lesions observed in the 
regenerating liver of Pcsk9-/- mice were efficiently prevented by feeding the mice a high 
cholesterol diet, indicating that, in mouse, loss of PCSK9 leads to a critical 
hypocholesterolemia. In agreement with its key regulatory role, PCSK9 is regulated at 
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the transcriptional level by sterols24, insulin, glucagon, ethinylestradiol and fasting25-27, 
but also at the protein level by hepatic furin28. 
Because human PCSK9 targets ex vivo human VLDLR15, and binds in vitro mouse 
VLDLR16, PCSK9 may also target VLDLR in humans. Whether an increased visceral fat 
deposition also occurs in humans lacking functional PCSK9 remains to be elucidated. 
Perigonadal fat is part of what is called the visceral adipose tissue, which correlates 
directly with obesity-related metabolic disease and coronary heart disease. However, it 
was recently reported that, within obese patients with similar levels of visceral adipose 
tissue, metabolic complications were more prevalent in those exhibiting higher intra-
hepatic triglyceride 29. In a clinical perspective, since Pcsk9-/- mice do not develop liver 
steatosis and are not prone to obesity, the administration of a PCSK9 inhibitor 
developed for hypercholesterolemia treatment should not result in adverse effects. 
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5.1.8. Figures and legends 
 
Figure 1. Pcsk9-/- mice accumulate fat in visceral adipose tissue. Visceral (perigonadal 
and perirenal), subcutaneous (pectoral and inguinal) and brown fat was dissected out 
from 26 and/or 10 week-old males (M) and females (F) and its weight expressed as the 
percentage of body weight. n = 4 to 15 mice per gender and genotype. Average ± SEM; 
*, P ≤ 0.05; **, P ≤ 0.005. 
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Figure 2. PCSK9 deficiency leads to adipocyte hypertrophy. Paraffin sections of WT and 
Pcsk9-/- perigonadal depots from 26 week-old mice were stained with hematoxylin and 
eosin (H&E) and the number of adipocytes/mm2 determined. n = 8 to 11 mice per gender 
and genotype. Average ± SEM; **, P ≤ 0.005; ***, P ≤ 0.0005. 
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Figure 3. In vivo dietary lipid uptake and ex vivo triglyceride synthesis are altered in 
Pcsk9-/- mice. A, Mice received a 3H-oleate fat load. After 3 hours, the 3H-oleate uptake 
into neutral lipids was evaluated in fat depots, muscle and liver and expressed in 
disintegrations per minute (dpm) /tissue; n = 8 to 10 mice per gender and genotype. B, 
Indicated tissues were incubated with 3H-glucose for 3 hours and their 3H-triglyceride 
content was assessed in triplicates;  n = 7 to 10 mice per gender and genotype. Average 
± SEM; *, P ≤ 0.05; **, P ≤ 0.005. 
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Figure 4. PCSK9 deficiency leads to adipocyte hypertrophy in a LDLR-deficient 
background. The number of adipocytes/mm2 was determined in paraffin sections of Ldlr-/- 
or Ldlr-/- Pcsk9-/- perigonadal depots from 26 week-old mice, as in Figure 2. n = 4 mice 
per gender and genotype. Average ± SEM; **, P ≤ 0.005; ***, P ≤ 0.0005. 
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Figure 5. VLDLR protein levels are higher in Pcsk9-/- perigonadal fat. Paraffin sections of 
26 week-old WT and Pcsk9-/- mice, or Ldlr-/- and Ldlr-/- Pcsk9-/- mice were incubated with 
a VLDLR antibody visualized using Alexa488-labeled secondary antibody (green 
labeling). The VLDLR labeling was expressed in arbitrary units (see Methods). n = 4 to 8 
mice per point. Average ± SEM; *, P ≤ 0.05; ***, P ≤ 0.0005. 
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Figure 6. Adipose VLDLR protein is regulated by circulating PCSK9. VLDLR 
immunohistochemistry was performed on female perigonadal sections from either Pcsk9-
/- littermates that did not or did receive a transgene expressing PCSK9 in the liver (top 
panels a and b; + circulating PCSK9) or from Pcsk9flox/flox (equivalent to WT) littermates 
that did not or did receive a transgene expressing Cre inactivating specifically the Pcsk9 
gene in hepatocytes (lower panels c and d; - circulating PCSK9). Average VLDLR 
labeling and plasma PCSK9 levels for these mice are shown, as well as for Vldlr-/- mice 
as negative controls. n = 4 to 5 mice per genotype; average ± SEM; *, P ≤ 0.05; **, P ≤ 
0.005; ***, P ≤ 0.0005. 
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5.1.9. Supplemental material  
Available at: http://atvb.ahajournals.org 
 
The proprotein convertase of the subtilisin/kexin type PCSK9 regulates 
triglyceride metabolism via VLDL receptor degradation 
By: Roubtsova et al. 
Online Methods 
Paraffin section analysis and immunohistochemistry 
For adipocyte counts, paraffin sections of perigonadal depots (5 μm thick) were stained 
with hematoxylin and eosin (Sigma Aldrich, Oakville, ON), rinsed with xylene and 
mounted in Entellan New from Merck (Darmstadt, Germany). Adipocytes were counted 
in 3 random fields on a selected section per mouse, and 4 or more mice were analyzed 
by gender and genotype.  
For VLDLR visualization, unparaffinized sections were incubated overnight at 
4°C with a mouse VLDLR antibody (1:300; R&D systems) under non-permeabilizing 
conditions, and then one hour at room temperature with Alexa Fluor 488-labeled anti-
goat IgGs (1:150; Invitrogen, Burlington, ON). Nuclei were counterstained with Hoechst 
dye (Sigma). Images were acquired using a Retiga EXi camera (Q-Imaging) mounted on 
a Leica DMRB microscope. Normalized total grey values (GVLDLR) from VLDLR labeling 
monochromatic images (8 bits  - 256 greyscale values) were obtained using Matlab 
R2010a (The MathWorks Inc.) by summing grey pixel values (threshold to the negative 
control value) and normalizing to the highest value. 
 
Intragastric Fat Administration 
After an overnight fast (16 h), olive oil containing 10 μCi of 3H-oleate was administered 
by gastric gavage1. Briefly, after sacrifice, tissues were excised and weighed. To 
measure 3H-oleate incorporation in tissular neutral lipids, the latter were extracted from 
tissue fragments of 10 to 50 mg and counted directly1. To assess the ex vivo triglyceride 
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synthesis, small tissue pieces (~15 µg) were incubated with 14C-glucose as previously 
reported2. After lipid extraction, triglycerides were measured and expressed as pmol/mg 
protein2. 
 
Quantitation of plasma PCSK9 by ELISA 
Mouse plasma were collected in EDTA coated Microtainer tubes (BD Biosciences, 
Fisher, ON) and 3 μL were used to measure PCSK9 using the CircuLex mouse/rat 
PCSK9 ELISA (MBL, Woburn, MA), according to the manufacturer’s recommendations. 
Statistical analysis 
Excel software was used for SEM and Student’s t-test calculations. 
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Methods for Online Figures 
Animals and treatments 
Mice were fed a Western diet TD.88137 that was obtained from Harlan Teklad (Madison, 
WI). 
Quantitative RT-PCR 
Total RNA from liver and perigonadal fat was extracted with TRIzol (Invitrogen). cDNA 
was generated from 250 ng of total RNA using a SuperScript II cDNA reverse 
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transcriptase (Invitrogen). cDNA amplification by quantitative PCR was done in a final 
volume of 10 μL using SYBR green SuperMix from Quanta (Gaitherburg, MD). cDNA 
quantitation of each gene of interest was performed using specific primers (see the 
Table below) with normalization to the TATA box protein (TBP) cDNA amplification and 
expressed as arbitrary units. 
Specific mouse cDNAs were amplified using the following primers:  
 
cDNA Forward primer (5’ -> 3’) Reverse primer (5’ -> 3’) 
TBP GCTGAATATAATCCCAAGCGATTT GCAGTTGTCCGTGGCTCTCT 
PCSK9 CAGGGAGCACATTGCATCC TGCAAAATCAAGGAGCATGGG 
VLDLR GGACATTGCAGCTCAGAAGCT CATCAATTGAGGCACTGAAGATG 
FAT/CD36 TGGTGATGTTTGTTGCTTTTATGAT GCTCATCCACTACTTATTTTCCATTCT 
LPL GTGGCCGAGAGCGAGAAC CCGTGTAAATCAAGAAGGAGTAGGTT 
LDLR GGAGATGCACTTGCCATCCT AGGCTGTCCCCCCAAGAC 
` 
Plasma cholesterol and triglyceride measurements 
Plasma was obtained by centrifugation (15 minutes at 850g at 4°C) of 250 μL of blood 
and kept at –20°C until assay. Total cholesterol and triglycerides were measured using 
the Infinity Thermo Electron Corporation (Melbourne, Australia) and Wako pure chemical 
industry (Osaka, Japan) kits, respectively. For lipoprotein profiles, plasma from 3 mice 
(300 μL) were pooled and analyzed by FPLC on a Superpose 6 column (Pharmacia, 
Sweden) at a flow rate of 0.5 mL/min. Cholesterol and triglycerides were then measured 
as above. After the fat load by gavage, triglycerides were measured in the plasma using 
a colorimetric enzymatic kit from Roche Applied Science. 
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Online Figure legends 
 
 
 
 
Online Figure I. Pcsk9-/- mice accumulate fat in visceral adipose tissue. Visceral 
(perigonadal and perirenal), subcutaneous (pectoral and inguinal) and brown fat was 
dissected out from 10 and/or 26 week-old males (M) and females (F) and its weight 
expressed as the percentage of body weight. n = 4 to 15 mice per gender and genotype. 
Average ± SEM; *, P ≤ 0.05; **, P ≤ 0.005. 
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Online Figure II. The body weight of Pcsk9-/- mice is moderately increased. WT and 
Pcsk9-/- males (M) and females (F) were fed either a regular diet and weighted at 10 or 
26 weeks of age (n = 14 to 15 mice per genotype and gender), or a Western diet (for 25 
weeks after weaning) and weighted weekly up to 28 weeks of age (one of three 
experiments, n = 5 mice per genotype and gender). Mean ± SEM; *, P ≤ 0.05. 
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Online Figure III. PCSK9 mRNA is poorly expressed in perigonadal depots. Quantitative 
RT-PCR using PCSK9 specific primers detected 140 and 180-fold less PCSK9 mRNA in 
perigonadal fat than in the liver in WT (open bars) males and females, respectively. 
These levels were not significantly affected in Ldlr-/- mice (dotted bars; see enlargement 
in the inset), except in the male liver (-39%). Average ± SEM; *, P ≤ 0.05; **, P ≤ 0.005. 
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Online Figure IV. Circulating and liver cholesterol and triglycerides levels are affected 
in Pcsk9-/- mice. While circulating cholesterol levels decreased in KO mice, circulating 
triglycerides levels tended to increase in 6 month-old mice fasted for 3 hours; n = 11 
mice. Average ± SEM; *, P ≤ 0.05; ***; P ≤ 0.0005). 
 
 
 
 
 
 
                                                                                                                                                                  94  
 
 
 
 
 
 
 
 
 
Online Figure V. Clearance of postprandial triglycerides in Pcsk9-/- mice was 
maintained. Concentrations of plasma triglycerides in millimoles/liter (mM) at 0, 1, 2 or 3 
hours following gavage with 200 μL of olive oil were obtained in males (left panel) or 
females (right panel). 
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Online Figure VI. VLDLR labeling is highly specific. Control Vldlr-/- (top panels) and 
Pcsk9-/- or  Pcsk9-/- Ldlr-/- (lower panels) perigonadal paraffin sections were 
simultaneously incubated with VLDLR antibody (see Methods). While a strong labeling 
was observed in the sections of PCSK9-deficient mice, virtually no labeling was detected 
in  Vldlr-/- sections. 
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Online Figure VII. VLDLR mRNA is modestly regulated in Pcsk9-/- mice. Quantitative 
RT-PCR was performed to assess the VLDLR expression in the liver and perigonadal 
depots of WT, Pcsk9-/-, Ldlr-/- and Ldlr-/- Pcsk9-/- mice. Values for male livers are 
expanded in the inset. n = 7 to 9 mice per point. Average ± SEM; *, P ≤ 0.05. 
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Online Figure VIII. LPL, CD36 and LDLR mRNA levels are almost not affected by 
PCSK9 and/or LDLR deficiencies. Quantitative RT-PCR was performed to assess 
lipoprotein lipase (LPL), CD36 and LDLR expression in perigonadal depots of WT, 
Pcsk9-/-, Ldlr-/- and Ldlr-/- Pcsk9-/- mice. n = 5 to 9 mice per point. Average ± SEM; *, P ≤ 
0.05. 
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CHAPTER 4:  
GENERAL DISCUSSION AND CONCLUSIONS 
 
6. General discussion 
The purpose of these two studies was to gain insight into the yet undisclosed biology 
of PCSK9. Although PCSK9 is considered a member of the PC family that activates or 
inactivates proprotein, nothing is known about its ultimate substrate. Apart from cleaving 
itself and mysteriously targeting the LDLR to the degradation pathway, less is known 
about other functions in non-hepatic tissue. One way of exploring the role of PCSK9 is 
by examining the state of protein deficiency or overexpression in an animal model. In 
this thesis, we investigated both aspects:  
• First, overexpressing Pcsk9 gene in mice leads to a phenotype of 
hypercholesterolemia and atherosclerotic calcification in aortic wall, which was 
accelerated by a Western diet.  
• Second, the lack of Pcsk9 gene in mice leads to a phenotype of mild visceral fat 
accumulation. The VLDLR accumulates in Pcsk9-/- fat tissue enhances TG trapping in 
adipose tissue. 
 
In both models we address medical concerns that will confront health professional 
treating patients harboring mutations in PCSK9 gene.  
 
 
In the case of a gain-of-function mutation in PCSK9, patients will develop familial 
hypercholesterolemia. If they survive coronary artery disease, they will encounter 
morbidities associated with premature calcification of the aorta, such as hypertension or 
embolizing calcified lesions. Conventional treatment modalities may lower cholesterol 
level and prevent coronary artery disease but might not necessary stop arterial 
calcification and aortic valve calcification. Furthermore conventional treatment may 
cause serious side effect or might be contra indicated in some medical conditions (Awan 
et al 2009). By using animal models, we could therefore test single and/or combination 
therapies to treat arterial calcification like; vitamin K, estrogen, selective estrogen 
receptor modulators, calcium channel blockers chelating and demineralization therapy 
(Wallin et al 2001). Following application of a new treatment combination we could then 
use the micro-CT technique we developed to evaluate each treatment modality. This is 
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the first study to characterize and utilize micro-CT in determining aortic calcification in 
Ldlr-/- and PCSK9 Tg mice which will lead to major impacts in biomedical research. 
 Hence, the evolution of vascular calcification appears to be, at least in part, 
independent of LDL-C levels (Awan et al 2008) and once osteoblast-like cells 
differentiate; the process may become only poorly reversible. Prospective from our 
studies in human and animal models have advanced the understanding of arterial 
calcification in the aorta in the following ways: 
1. Long-term clinical data in human indicate that despite marked LDL-C lowering, 
arterial calcification progress in an age-dosage manner and contribute to significant 
life long morbidity and associate with important complications when surgical 
procedures are needed (Grenon et al 2007). Consequently, experts in the field have 
noticed that once calcified, tendinous xanthomas fail to regress. From our mice 
models we have simulated FH homozygote and heterozygote by using LDLR-
deficient and PCSK9 Tg mice. Then we confirmed the age- and gene-dosage effects 
we see in human, and confirmed that calcification do not correlate with circulating 
cholesterol levels.  Therefore early screen and detection with a sensitive method like 
CT and micro-CT scan will help disease understanding, evaluation of treatment 
response and planning future surgical interventions. 
2. Arterial calcification stands in sharp contrast with disturbances in calcium and 
phosphate metabolism of end-stage renal failure. Even when extracorporeal LDL-C 
filtration techniques (LDL aphaeresis) are used to normalize plasma LDL-C, patients 
do not suffer calcium levels alterations (Awan et al 2008). In arterial calcification, 
bone and calcium homeostasis do not appear to be significantly disturbed in LDL-
deficient patients as seen in a recent publication (Awan et al 2010). In the same 
study we reported that despite apparently normal levels of calcium, phosphate and 
bone mineral density, a negative correlation between osteocalcin levels and AoCS 
was found. This suggests an alteration in osteoblast function that may further fuel 
extra-skeletal tissue with the necessary elements to start calcifying. Therefore it 
would be of interest to examine bone metabolism in our established animal models.  
3. LDLR-deficient mice developed calcium deposition in the tunica intima space of the 
aorta similar to human data (Awan et al 2008). This implies that early sub-endothelial 
damage caused by foam cell formation during the atherosclerosis process results in 
accumulation of structural matrix (collagen) for which calcium is deposited within. It is 
                                                                                                                                                                  101  
thought that the structural matrix is laid down by differentiated local or stromal cells 
that acquire an osteoblast-like phenotype. A proposed unifying hypothesis links 
atherosclerosis risk factors, inflammatory mediators with the activation of the 
Wnt/Lrp5 and Runx2/Cbfa1 pathways and osteoblast differentiation (O’Brien 2006, 
Shao et al 2010) (Figure 7). Therefore it would be beneficial to develop lifelong 
treatment to prevent early intimal injury and prevent the osteoblast differentiation 
processes. 
 
In the first manuscript without any doubt we show that the LDLR-deficient mice and 
PCSK9 Tg mice develop significant aortic calcification, but not WT mice fed western diet 
by micro-CT and conventional histological analysis. This signifies a role of LDLR in aortic 
calcification. However our data are mostly descriptive and clearly lack mechanistic 
insight but still represent the first model of aortic calcification that mimics the human 
disease in FH. The intriguing finding that diet-induce hypercholesterolemia to levels that 
of homozygous FH alone does not lead to arterial calcification is a key finding that will 
completely revolutionize the concept of arterial calcification. Therefore we propose that 
arterial calcification needs multiple factors one for initiation in the form of endothelial 
insult (oxidized LDL, angiotensin II, and cytokines) and factors one for maintenance in 
the form of genetic predisposition (lacking a cell surface receptor, gaining or lacking a 
calcium regulatory protein). We are currently considering a model whereby fibroblasts or 
myofibroblasts cell-lines on LDLR-deficient background and through a variety of initiating 
factors that leads to osteoblast dedifferentiate in our future work. In turn, these initiating 
factors we expect will trigger the bone morphogenic protein 2 (BMP2) activation of Msx2 
and the Wnt/Lrp5/β-catenin signaling pathway, as well as the Runx2/Cbfa1 pathway 
mediated activation of osteoblast transformation. In conjunction it would be of interest to 
use the Ldlr-/- animal model to validate the osteoblast/renal mild dysfunction that we 
observed in FH patients in our recent publication (Awan et al 2010) or test a type of 
preventive intervention as suggested in the discussion previously. Any of these 
experiments would be of certain clinical important basically because LDL-C lowering with 
statins or exetimibe in the prevention of aortic calcification has not met with success. 
Complexes as it is the mystery of premature arterial calcification is not unfolded 
completely and many scientific breakthroughs are need to understand and modulate this 
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process and achieve better patient outcome thus we trust that our model will contribute 
to identifying of novel therapies.  
Regarding the reason why other investigators who have used Ldlr-/- mice have not 
and do not report calcification are due to several factors. The investigators did rarely 
keep mice for more that a year and/or included high fat diet as a condition for developing 
atherosclerosis unlike our old mice on show diet. Conventional methods are not 
sensitive to pick up calcium crystals unlike micro-CT. Old studies reported these arterial 
calcifications as late passive complication of atherosclerosis and not a dynamic process. 
Finally the distention between atherosclerotic plaques and atherosclerotic calcification is 
not often made in the literature. Our study examines aortic calcification, using a novel 
micro-CT method to better evaluate premature aortic calcification. This is of particular 
interest since cardiovascular calcification induces vascular morbidities in FH patients 
that do not seem to be prevented by conventional therapies. Unfortunately we did not 
provide direct Ldlr +/- (heterozygote FH) data as to whether they have the same disease 
in mice and this is because we believe that the best estimate of the heterozygous state 
is represented by the PCSK9 Tg leading to an accurate intermediate phenotype and that 
is not compensated as in Ldlr +/- mice. This is further supported by western blotting 
analysis of hepatic LDLR protein in WT, Ldlr-/- and PCSK9 Tg showing the intermediated 
LDLR protein expression in PCSK9 Tg (Zaid et al 2008). 
Another interesting finding is that PCSK9 Tg mice presented with slightly higher 
plasma cholesterol than that of WT mice when fed a regular chow diet did not develop 
much calcification at 18 month (n=2). In part, this problem was resolved when the 
PCSK9 Tg mice (n=9) were fed a Western diet for 12 months. However these PCSK9 Tg 
mice presented later with lower plasma triglycerides and more weight again in compare 
to Ldlr-/- mice. This observation became challenging to understand in light of our second 
paper where we show that PCSK9 degrades not only LDLR but also VLDLR (Roubtsova 
et al 2011). We think that this effect might in part be due to the fact that PCSK9 Tg mice 
reduce LDLR expression to approximately 50% of WT mice and therefore the expected 
phenotype (i.e. lipid levels) will be less severe than the Ldlr-/-, however the weight issue 
is more related to the relative weight loss in Ldlr-/- (statistically significant) rather than the 
weight gain in PCSK9 Tg (statistically not significant). This is because Ldlr-/- mice are 
generally sicker (CAD) and when fed Western diet they tend to develop fatty livers that 
later progress to liver cirrhosis and weight loss. 
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In the case of loss-of-function mutations in PCSK9 or the future use of PCSK9 
inhibitors, the fat accumulation in perigonadal and perirenal pads did not translate to 
significant weight gain and/or lead to overt diabetes in mice. Therefore we stress again 
the fact that the site of fat accumulation matters the most. In contrast to harmful visceral 
obesity in human due to the accumulation of omental fat and pericardial fat that gain 
easy access to systematic circulation, perigonadal and perirenal fat has poor access to 
systematic circulation due to the distal location of large vessels. Therefore perigonadal 
and perirenal fat pads resemble a safe storage of access fat without adipokines, 
adiponectin, leptin and resistin induction into the systemic circulation. In addition, 
unpublished data from our lab show no upregulation of inflammatory mediators in 
PCSK9-deficient mice compare to WT mice. A recent paper indicated that intra hepatic 
fat accumulation and not the visceral fat accumulation is the cause of insulin resistance 
(Fabbrini et al 2009). However impaired glucose tolerance (Mbikay et al 2010) may be 
associated with perigonadal and perirenal fat accumulation in PCSK9-deficient mice 
remotely, or due to lipotoxicity induced by higher LDLR levels in β-cells of PCSK9 KO 
mice (Mbikay et al 2010).  
 
This provides compelling rationale to examine the long-term effects of early and 
sustained intervention in hypercholesterolemia, to prevent or delay atherosclerosis and 
its complications. A potential therapeutic approach is to develop newer and improved 
lipid-lowering agents that are easily administered and can be used in combination with 
current medications. PCSK9 inhibitor may very much fit this definition but safety profile 
must be examined carefully. Here are some prospective from studying PCSK9-
deficiency models to understand the biological effect of a PCSK9- inhibitor: 
1. As many medications tend to increase weight it is of concern, as we intend to fight 
risk factors of atherosclerosis and CVD we do not want to accidentally induce one by 
our newer medication. The observation of abdominal adiposity that was associated 
with PCSK9-deficient mice was examined here and a new role of PCSK9 was 
identified in fat tissue. Therefore, any long-term monitoring of PCSK9-inhibitor use 
should include weight gain, obesity and an insulin resistance monitoring. 
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2. The site of obesity or fat accumulation is the main determinant of health related 
complication. Abdominal obesity or apple-like fat distribution is more related to 
metabolic syndrome than pear-like fat distribution (Lebovitz et al 2003). Abdominal 
obesity were fat accumulate in omental fat and pericardial fat is more harmful than 
perigonadal and perirenal fat accumulation. This is because the more the fat pad is 
proximal to systemic circulation the more likely it is to exhibit insulin resistance. 
However, at this point we could not exclude the late onset of glucose intolerance 
(Mbikay et al 2010) associated with perigonadal and perirenal fat accumulation in 
PCSK9-deficient mice. Therefore, more studies are needed to explore this risk. 
3. Additional evidence of new PCSK9 biology in fat metabolism in adipose tissue since 
PCSK9 bind the EGF-like A domain of LDLR, thus may bind similarly VLDLR a close 
family members. Therefore PCSK9 regulate VLDLR in fat tissue, FFA trafficking and 
adiposity TG synthesis. Other LDLR family members may lead to more PCSK9 
biology role in different tissues. 
 
In the second manuscript we address the conflicting data to wither the PCSK9 bind 
VLDLR or not. Ex vivo and in vitro studies showed that PCSK9 binds and induces the 
degradation of the VLDLR protein by assessing the receptor levels in various cell lines 
overexpressing PCSK9 and direct binding of a synthetic EGF-A repeat to the LDLR 
(Poirier et al 2008, Shan et al 2008). However, leaders in this field, Hobbs and 
colleagues, had concluded in an earlier study that PCSK9 did not bind the VLDLR, due 
to amino acid differences in its EGF-A repeat domain (Zhang et al 2007). Thus, this 
issue remains controversial prior to this day. Even though the activity of PCSK9 on 
VLDLR could be anticipated, we think that the demonstration of its reality, and the 
description of the adipose phenotypes associated with the absence of a PCSK9 control 
on the VLDLR protein, constitute a key work to fully understand the pivotal role of 
PCSK9 in connecting different metabolic pathways. Therefore we do not exclude that 
PCSK9 regulates (directly or indirectly) other key receptors or targets that may 
contribute to the amplitude of the phenotypes. However, the phenotypes that 
characterize Vldlr-/- mice and the reported functions of the VLDLR in lipoprotein binding 
corroborate our data. We are indeed very interested in considering the consequence of 
the absence of PCSK9 on the FFA uptake machinery; this could be part of a future work. 
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It seems that FFA catabolism is higher in females specifically in the inguinal pad, raising 
the question of an activation of PPAR alpha pathway. PPAR alpha may indeed be 
involved in this 81% increase in FFA catabolism. It is well shown that FFA uptake, 
oxidation and VLDLR mRNA could be co-regulated. However, it is not obvious without 
further analyses to determine the contribution of PPAR (peroxisome proliferator-
activated receptor) alpha versus that of PPAR gamma or other transcription factors that 
were shown to regulate these pathways. 
However the evidence for PCSK9 targeting VLDLR in our study was the 
quantification of VLDLR expression by immunohistochemistry. We acknowledge that 
such experiments are somewhat hard to control, since the signal generated by the 
antibodies used could also be derived from cross-reacting antigens. We have thus 
repeated the immunohistochemical analyses of the VLDLR labeling in WT and Ldlr-/- 
backgrounds with the inclusion of negative controls from Vldlr-/- mice that we purchased 
from The Jackson Laboratory. The finding that the LDLR and VLDLR are controlled by 
the same mechanism (PCSK9) in the same direction therefore is novel. Thus circulating 
PCSK9 has a pivotal role in coordinating between peripheral fatty acid uptake and liver 
lipoprotein uptake, via regulating cell surface levels of VLDLR and LDLR resulting in 
slowing down lipoproteins catabolism, and maintain proper circulating levels of 
cholesterol and triglycerides. In agreement with its role, PCSK9 is regulated at the 
transcriptional level by sterols, insulin, glucagon, ethinylestradiol and fasting, but also at 
the protein level by hepatic furin. 
In this study we underline the phenotype of PCSK9 deficiency in females where it is 
more severe than men, in terms of increase VLDLR protein in fat tissue. However this 
did not translate into massive fat accumulation. Therefore this work does not suggest 
that PCSK9 inhibition could lead to harmful increase of visceral fat, in particular in 
women as the reader might conclude. This is because in the complete absence of 
PCSK9, likely not achieved by any potential drug, the weight gains are quite low, even 
when the mice were fed a Western diet and it is localized in fat pads only. In addition, 
Fabbrini et al showed that fat accumulation is more deleterious when it occurs in ectopic 
sites other than fat pads where they might cause organ dysfunction. Although the 
experiments performed in the second paper were not designed to evaluate the 
hyperplasia of the adipocytes, therefore can not be excluded, we provide sound 
evidences from paraffin blocks containing entire perigonadal pad sections every 200 
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micrometers with a highly reproducible counts for the number of cells per field, indicating 
that the size of the adipocytes in Pcsk9-/- is quite homogenously hypertrophied 
throughout the tissue with no evidence of hyperplasia suggest that hyperplasia is likely 
not a major issue in the Pcsk9-/- adipose tissue. The perfect experiment to monitor any 
hyperplasic trend in Pcsk9-/- perigonadal pads therefore would be to dissociate the 
adipocytes by digestion and to count them. 
 
8. Conclusions 
 
7.1. Article 1  
1. We provided mice models of moderate to extensive vascular calcification that 
replicate the disease observed in humans. These two animal models resembling 
absolute LDLR-deficiency and low LDLR-availability. The latter phenotype is 
mimicked by overexpression of PCSK9. 
2. We validated a sensitive technique to quantify aortic calcification in murine 
models using micro-CT. This method proved to be precise, quantifiable and 
informative.  
3. The results of the current study suggest that aortic calcification is associated with 
ageing and LDLR-deficiency, and is accelerated by a Western diet. 
4. PCSK9 Tg confirmed the possible role of LDLR in calcium deposition. 
5. The two models should facilitate studies on both the pathophysiology of vascular 
calcification and the efficacy of different treatment regimens. 
6. The mechanism of aortic calcification in FH could not be elucidated from this 
work, but the mouse models have sub-endothelial, tunica intima type of 
calcification similar to human, suggesting an inflammatory, proliferative and 
remodeling mechanism. 
7. Future therapy would be most likely combination: pyrophosphate inhibitors, 
chelating therapy, vitamin K, estrogen, selective estrogen receptor modulators 
and calcium channel blockers 
 
The following figure depicts the pathways that we are planning to test in our 
animal model in our effort of understand the molecular bases of aortic calcification in 
FH (Figure 1). 
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Figure 1.  
Future experiments to identify 
the mechanism of aortic 
calcification. LDLR-deficiency 
may trigger Msx2 and the 
Wnt/Lrp5/β-catenin signaling 
pathway, as well as the 
Runx2/Cbfa1 pathway mediated 
activation of osteoblast 
transformation. 
 
7.2. Article 2 
1. We investigated the role of PCSK9 in adipose tissue metabolism and potential 
impact of PCSK9 lost-of-function mutations or the effect of a PCSK9 inhibitor on 
fat deposition. 
2. Pcsk9-/- was associated with adipocyte hypertrophy, adipocytes increased in vivo 
fatty acid uptake and adipocyte ex vivo triglyceride synthesis, in an LDLR 
independent fashion. 
3. By immunohistochemistry we showed that Pcsk9-/- males and females exhibit 4- 
and 40-fold higher cell surface levels of VLDLR in perigonadal depots, 
respectively.  
4. Specific inactivation of PCSK9 in the liver of WT females led to 50-fold higher 
levels of perigonadal VLDLR. 
5. Expression of PCSK9 in the liver of female Pcsk9-/- mice re-established both 
circulating PCSK9 and normal VLDLR levels.  
6. PCSK9 regulates VLDLR protein levels in adipose tissue. This regulation is 
achieved by circulating PCSK9 that entirely originates from the liver.  
7. PCSK9 is thus pivotal in fat metabolism: it maintains high circulating cholesterol 
levels via hepatic LDLR degradation, but also limits visceral adipogenesis likely 
via VLDLR regulation. 
8. Since weight gain in PCSK9-deficent mice was minimal, it would be of great 
interest to examine the residual affect of visceral fat accumulation on the long-
term insulin resistance development. 
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The following figure shows a suggested model of PCSK9 mechanism of action in 
liver and fat tissue in light of our recent work (Figure 2). 
 
 
Figure 2.   
A model of PCSK9 
mechanism of 
action in different 
tissue. Both the 
LDLR and PCSK9 
in the liver are 
regulated by 
SREBP-2. In the 
liver PCSK9 
targets the LDLR 
degradation 
intracellular and 
extracellular while 
the circulating 
PCSK9 originating 
from the liver 
distally targets the 
VLDLR 
degradation at the 
site of fat tissue.  
` 
PCSK9 inhibition is a very promising class of drugs that will become a perfect 
add-on to statin or an alternative to statin in statin intolerant patients due to its unique 
mode of action. Currently several registered clinical trials using deferent approaches 
to inhibit PCSK9 reaching phase I and II. With PCSK9 inhibitors assisted for 
ascending multiple dose, safety, tolerability, pharmacokinetics, and 
pharmacodynamics it is only a matter of time until they will become part of our 
practice. Therefore our attempt and many others are focused on the prediction of 
these future drugs on cardiovascular health. 
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